<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        20-828-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VFEND 40MG/ML POWDER FOR SUSPENSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORICONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1470.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Fareva Amboise" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Fareva Amboise
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VFEND contains the active substance voriconazole. VFEND is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.</p><p>&nbsp;</p><p>It is used for the treatment of patients (adults and children over the age of 2) with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; invasive aspergillosis (a type of fungal infection due to <em>Aspergillus sp</em>),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; candidaemia (another type of fungal infection due to <em>Candida sp</em>) in non-neutropenic patients (patients without abnormally low white blood cells count),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious invasive <em>Candida sp.</em> infections when the fungus is resistant to fluconazole (another antifungal medicine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious fungal infections caused by <em>Scedosporium sp.</em> or <em>Fusarium sp</em>. (two different species of fungi).</p><p>&nbsp;</p><p>VFEND is intended for patients with worsening, possibly life-threatening, fungal infections.</p><p>&nbsp;</p><p>Prevention of fungal infections in high risk bone marrow transplant recipients.</p><p>&nbsp;</p><p>This product should only be taken under the supervision of a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take VFEND</strong></p><p>If you are allergic to voriconazole or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p>It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.</p><p>&nbsp;</p><p>The medicines in the following list must not be taken during your course of VFEND treatment:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Terfenadine (used for allergy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Astemizole (used for allergy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride (used for stomach problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pimozide (used for treating mental illness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine (used for irregular heart beat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivabradine (used for symptoms of chronic heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used for treating tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efavirenz (used for treating HIV) in doses of 400 mg and above once daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine (used to treat seizures)&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital (used for severe insomnia and seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sirolimus (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ritonavir (used for treating HIV) in doses of 400mg and more twice daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (herbal supplement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Naloxegol (used to treat constipation specifically caused by pain medicines, called opioids, (e.g., morphine, oxycodone, fentanyl, tramadol, codeine))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tolvaptan (u<strong>s</strong>ed to treat hyponatremia (low levels of sodium in your blood) or to slow kidney function decline in patients with polycystic kidney disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lurasidone (used to treat depression)Venetoclax (used to treat patients with chronic lymphocytic leukaemia-CLL)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking VFEND if:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an allergic reaction to other azoles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are suffering from, or have ever suffered from liver disease. If you have liver disease, your doctor may prescribe a lower dose of VFEND. Your doctor should also monitor your liver function while you are being treated with VFEND by doing blood tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are known to have cardiomyopathy, irregular heart beat, slow heart rate or an abnormality of electrocardiogram (ECG) called &lsquo;long QTc syndrome&rsquo;.</p><p>&nbsp;</p><p>You should avoid any sunlight and sun exposure while being treated. There is an increased chance of skin toxicity while taking VFEND. This can happen with or without taking other medicines like methotrexate. It is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun&rsquo;s UV rays can occur. This may be further increased by other medicines that sensitise the skin to sunlight, like methotrexate. These precautions are also applicable to children.</p><p><u>&nbsp;</u></p><p>While being treated with VFEND:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor immediately if you develop</p><p>o&nbsp;&nbsp; sunburn</p><p>o&nbsp;&nbsp; severe skin rash or blisters</p><p>o&nbsp;&nbsp; bone pain</p><p>&nbsp;</p><p>If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis. There is a small chance that skin cancer could develop with long-term use of VFEND.</p><p>&nbsp;</p><p>If you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol which may lead to symptoms such as: chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, please tell your doctor.</p><p>&nbsp;</p><p>If you develop signs of &lsquo;Cushing&rsquo;s syndrome&rsquo; where the body produces too much of the hormone cortisol</p><p>which may lead to symptoms such as: weight gain, fatty hump between the shoulders, a rounded face, darkening of the skin on the stomach, thighs breasts, and arms, thinning skin, bruising easily, high blood sugar, excessive hair growth, excessive sweating, please tell your doctor.</p><p>&nbsp;</p><p>Your doctor should monitor the function of your liver and kidney by doing blood tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>VFEND should not be given to children younger than 2 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and VFEND</strong></p><p>Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those that are obtained without a prescription.</p><p>&nbsp;</p><p>Some medicines, when taken at the same time as VFEND, may affect the way VFEND works or VFEND may affect the way they work.</p><p>&nbsp;</p><p>Tell your doctor if you are taking the following medicine, as treatment with VFEND at the same time should be avoided if possible:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ritonavir (used for treating HIV) in doses of 100 mg twice daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glasdegib (used for treating cancer) &ndash; if you need to use both drugs your doctor will monitor your heart rhythm frequently</p><p>&nbsp;</p><p>Tell your doctor if you are taking either of the following medicines, as treatment with VFEND at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifabutin (used for treating tuberculosis). If you are already being treated with rifabutin your blood counts and side effects to rifabutin will need to be monitored.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used to treat epilepsy). If you are already being treated with phenytoin your blood concentration of phenytoin will need to be monitored during your treatment with VFEND and your dose may be adjusted.</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/ or VFEND are still having the desired effect:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol; used to &nbsp;&nbsp; slow down clotting of the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzodiazepines (e.g., midazolam, triazolam) (used for severe insomnia and stress)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Omeprazole (used for treating ulcers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives (if you take VFEND whilst using oral contraceptives, you may get side effects such as nausea and menstrual disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (used for treating cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tretinoin (used to treat leukaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indinavir and other HIV protease inhibitors (used for treating HIV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as VFEND)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methadone (used to treat heroin addiction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alfentanil and fentanyl<s> </s>and other short-acting opiates such as sufentanil (painkillers used for surgical procedures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxycodone and other long-acting opiates such as hydrocodone (used for moderate to severe pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluconazole (used for fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Everolimus (used for treating advanced kidney cancer and in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Letermovir (used for preventing cytomegalovirus (CMV) disease after bone marrow transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivacaftor: used to treat cystic fibrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flucloxacillin (antibiotic used against bacterial infections)</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>VFEND must not be taken during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while taking VFEND.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>VFEND may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Contact your doctor if you experience this.</p><p>&nbsp;</p><p><strong>VFEND contains sucrose</strong></p><p>This medicine contains 0.54g sucrose per ml of suspension. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking VFEND. This should be taken into account in patients with diabetes mellitus. May be harmful to the teeth.</p><p>&nbsp;</p><p><strong>VFEND contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per 5&nbsp;ml of suspension, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><strong>VFEND contains benzoate salt/sodium</strong></p><p>This medicine contains 12&nbsp;mg benzoate salt in each 5&nbsp;ml dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor will determine your dose depending on your weight and the type of infection you have.</p><p>&nbsp;</p><p>The recommended dose for adults (including elderly patients) is as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>Oral suspension </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Patients 40 kg and above</p></td><td><p>Patients less than 40 kg</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Dose for the first 24 hours </strong></p></td><td><p>10 ml (400 mg) every 12</p></td><td><p>5 ml (200 mg) every 12</p></td></tr><tr><td style="vertical-align:top"><p>(Loading Dose)</p></td><td><p>hours for the first 24 hours</p></td><td><p>hours for the first 24 hours</p></td></tr><tr><td><p><strong>Dose after the first 24 hours </strong>(Maintenance Dose)</p></td><td><p>5 ml (200 mg) twice a day</p></td><td><p>2.5 ml (100 mg) twice a day</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may increase the daily dose to 7.5 ml (300 mg) twice a day.</p><p>&nbsp;</p><p>The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>The recommended dose for children and teenagers is as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>Oral suspension </strong></p></td></tr><tr><td><p>Children aged 2 to less than 12&nbsp;years and teenagers aged 12 to 14 years weighing less than 50&nbsp;kg</p></td><td><p>Teenagers aged 12 to 14 years weighing 50&nbsp;kg or more; and all teenagers older than 14</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose for the first 24 hours </strong></p><p>(Loading Dose)</p></td><td><p>Your treatment will be started as an infusion</p></td><td><p>10 ml (400&nbsp;mg) every 12 hours for the first 24 hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose after the first 24 hours </strong></p><p>(Maintenance Dose)</p></td><td><p>0.225 ml/kg (9&nbsp;mg/kg) twice a day</p><p>[a maximum dose of 8.75 ml (350&nbsp;mg) twice daily]</p></td><td><p>5 ml (200&nbsp;mg) twice a day</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may increase or decrease the daily dose.</p><p>&nbsp;</p><p>Take your suspension at least one hour before, or two hours after a meal.</p><p>&nbsp;</p><p>If you or your child are taking VFEND for prevention of fungal infections, your doctor may stop giving VFEND if you or your child develop treatment related side effects.</p><p>&nbsp;</p><p>VFEND suspension should not be mixed with any other medicine. The suspension should not be further diluted with water or any other liquids.</p><p>&nbsp;</p><p><strong>Instructions to constitute the suspension: </strong></p><p><strong>It is recommended that your pharmacist constitutes VFEND suspension before giving it to you.</strong> VFEND suspension is constituted if it is in a liquid form. If it appears to be a dry powder you should constitute the oral suspension by following the instructions below.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tap the bottle to release the powder.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the cap.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add 2 measuring cups (measure cup included in the carton) of water (total of 46 ml) to the bottle. Fill the measuring cup to the top of the marked line then pour the water into the bottle. You should always add a total of 46 ml of water irrespective of the dose you are taking.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the cap and shake the bottle vigorously for about 1 minute. Following constitution, the total volume of the suspension must be 75 ml.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the cap. Press the bottle adaptor into the neck of the bottle (as shown on figure below). The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Write the date of expiry of the constituted suspension on the bottle label (the shelf-life of the constituted suspension is 14 days). Any unused suspension should be discarded after this date.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_6" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:315pt;height:127pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop=".25" cropbottom="16924f" cropleft="9738f" cropright="12891f"/>
</v:shape><![endif]--><img width="420" height="169" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p><strong>Instructions for use: </strong></p><p>Your pharmacist should advise you how to measure the medicine using the multi-dosing oral syringe provided in the pack. Please see instructions below before using VFEND suspension.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the closed bottle of constituted suspension for approximately 10 seconds before use. Remove the cap.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While the bottle is upright, on a flat surface, insert the tip of the oral syringe into the adaptor.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle upside down while holding the oral syringe in place. Slowly pull back the plunger of the oral syringe to the graduation mark that marks the dose for you.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If large bubbles can be seen, slowly push the plunger back into the syringe. This will force the medicine back into the bottle. Repeat step 3 again.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle back upright with the oral syringe still in place. Remove the oral syringe from the bottle.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the tip of the oral syringe into the mouth. Point the tip of the oral syringe towards the inside of the cheek. SLOWLY push down the plunger of the oral syringe. Do not squirt the medicine out quickly. If the medicine is to be given to a child, make sure the child is sitting, or is held, upright before giving the medicine.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the cap on the bottle, leaving the bottle adaptor in place. Wash the oral syringe as instructed below.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_8"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:315.5pt;height:98.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="421" height="131" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3/4&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6</p><p><strong>Cleaning and storing the syringe: </strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The syringe should be washed after each dose. Pull the plunger out of the syringe and wash both parts in warm soapy water. Then rinse with water.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry the two parts. Push the plunger back in to the syringe. Keep it in a clean safe place with the medicine.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more VFEND than you should</strong></p><p>If you take more suspension than prescribed (or if someone else takes your suspension) you must seek medical advice or go to the nearest hospital casualty department immediately. Take your bottle of VFEND suspension with you. You may experience abnormal intolerance to light as a result of taking more VFEND than you should.</p><p>&nbsp;</p><p><strong>If you forget to take VFEND</strong></p><p>It is important to take your VFEND suspension regularly at the same time each day. If you forget to take one dose, take your next dose when it is due. Do not take a double dose to make up for the forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking VFEND</strong></p><p>It has been shown that taking all doses at the appropriate times may greatly increase the effectiveness of your medicine. Therefore unless your doctor instructs you to stop treatment, it is important to keep taking VFEND correctly, as described above.</p><p>&nbsp;</p><p>Continue taking VFEND until your doctor tells you to stop. Do not stop treatment early because your infection may not be cured. Patients with a weakened immune system or those with difficult infections may require long-term treatment to prevent the infection from returning.</p><p>&nbsp;</p><p>When VFEND treatment is stopped by your doctor you should not experience any effects.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.</p><p>&nbsp;</p><p><strong>Serious side effects &ndash; Stop taking VFEND and see a doctor immediately</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice; Changes in blood tests of liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people</p><p>&nbsp;</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment (change in vision including blurred vision, visual colour alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes)</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, diarrhoea</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the extremities</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pains</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes</p><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people</p><p>&nbsp;</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the sinuses, inflammation of the gums, chills, weakness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low numbers of some types, including severe, of red (sometimes immune-related) and/or white blood cells (sometimes with fever), low numbers of cells called platelets that help the blood to clot</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar, low blood potassium, low sodium in the blood</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, depression, confusion, agitation, inability to sleep, hallucinations</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin sensations, increase in muscle tone, sleepiness, dizziness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute breathing difficulty, chest pain, swelling of the face (mouth, lips and around eyes), fluid accumulation in the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, indigestion, inflammation of the lips</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice, inflammation of the liver and liver injury</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes which may lead to severe blistering and peeling of the skin characterized by a flat, red area on the skin that is covered with small confluent bumps, redness of the skin</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchiness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure, blood in the urine, changes in kidney function tests</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sunburn or severe skin reaction following exposure to light or sun</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin cancer</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the thin tissue that lines the inner wall of the abdomen and covers the abdominal organ</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph glands (sometimes painful), failure of blood marrow, increased eosinophil</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depressed function of the adrenal gland, underactive thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with balance or coordination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the brain&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision, serious conditions of the eye including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased sensitivity to touch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing difficulties, ringing in the ears, vertigo</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of certain internal organs- pancreas and duodenum, swelling and inflammation of the tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged liver, liver failure, gallbladder disease, gallstones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the kidney, proteins in the urine, damage to the kidney</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very fast heart rate or skipped heartbeats, sometimes with erratic electrical impulses</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal electrocardiogram (ECG)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood cholesterol increased, blood urea increased</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions (sometimes severe), including life-threatening skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth, inflammation of the skin, hives, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion site reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction or exaggerated immune response</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tissue surrounding the bone&nbsp;</p><p>&nbsp;</p><p>Rare: may affect up to 1 in 1000 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overactive thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deterioration of brain function that is a serious complication of liver disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of most fibers in the optic nerve, clouding of the cornea, involuntary movement of the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bullous photosensitivity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disorder in which the body&rsquo;s immune system attacks part of the peripheral nervous system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart rhythm or conduction problems (sometimes life threatening)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life threatening allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder of blood clotting system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions (sometimes severe), including rapid swelling (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or sore patches of thick, red skin with silvery scales of skin, irritation of the skin and mucous membranes, life-threatening skin condition that causes large portions of the epidermis, the skin&#39;s outermost layer, to detach from the layers of skin below</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small dry scaly skin patches, sometimes thick with spikes or &lsquo;horns&rsquo;</p><p>&nbsp;</p><p>Side effects with frequency not known:</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Freckles and pigmented spots</p><p>&nbsp;</p><p>Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called cutaneous lupus erythematosus</p><p>&nbsp;</p><p>As VFEND has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidney by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.</p><p>&nbsp;</p><p>There have been reports of skin cancer in patients treated with VFEND for long periods of time.</p><p>&nbsp;</p><p>Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis. Elevated liver enzymes were also observed more frequently in children.</p><p>&nbsp;</p><p>If any of these side effects persist or are troublesome, please tell your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> </strong><strong>GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Powder for oral suspension: store at 2&deg;C - 8&deg;C (in a refrigerator) before constitution.</p><p>For the constituted suspension:</p><p>Store below 30&deg;C.&nbsp;</p><p>Do not refrigerate or freeze.</p><p>Store in the original container.</p><p>Keep the container tightly closed.</p><p>Any remaining suspension should be discarded 14 days after constitution.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer required. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is voriconazole. Each bottle contains 45 g of powder providing 70&nbsp;ml of suspension when constituted with water as recommended. One ml of the constituted suspension contains 40 mg voriconazole. (See section 3 &lsquo;How to take VFEND&rsquo;).</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sucrose; silica colloidal; titanium dioxide; xanthan gum; sodium citrate; sodium benzoate; citric acid; natural orange flavour (see section 2, VFEND 40&nbsp;mg/ml powder for oral suspension contains sucrose, benzoate salt (sodium benzoate) and sodium).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VFEND is supplied as a white to off-white powder for oral suspension providing a white to off-white, orange flavoured suspension when constituted with water.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Europe MA EEIG, Belgium.</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer </strong></p><p>Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poc&eacute;-sur-Cisse, France.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيفند على المادة الفعالة فوريكونازول. فيفند هو دواء مضاد للفطريات، ويعمل عن طريق قتل أو إيقاف نمو الفطريات المسبِبة للعدوى.</p><p dir="RTL">يستخدم فيفند لعلاج المرضى (البالغين والأطفال الأكبر من سنتين) المصابين بـ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الرشاشيات الاجتياحي (نوع من أنواع العدوى الفطرية التي يسببها جنس الرشاشيات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء المبيضة في الدم (نوع آخر من العدوى الفطرية التي يسببها جنس المبيضات) في المرضى غير المصابين بنقص العدلات (المرضى غير المصابين بانخفاض تعداد خلايا الدم البيضاء بشكل غير طبيعي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى جنس المبيضات الخطيرة الاجتياحية عندما تكون الفطريات مقاومة للعلاج بفلوكونازول (دواء آخر مضاد للفطريات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية الخطيرة التي يسببها جنس البوغانة أو جنس الفطريات المغزلاوية. (نوعان مختلفان من الفطريات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيفند مخصص للمرضى المصابين بعدوى فطرية متفاقمة ويُحتمل أن تكون مهددة للحياة.</p><p dir="RTL">منع الإصابة بعدوى فطرية في المرضى الذين خضعوا لعملية زرع نخاع العظم المعرضين لخطر مرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استعمال هذا المنتج إلّا تحت إشراف أحد الأطباء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال فيفند</strong></p><p dir="RTL">إذا كنت مصابًا بالحساسية تجاه فوريكونازول أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم للغاية أن تخبر طبيبك أو الصيدلي بأي أدوية أخرى تتناولها أو تناولتها في السابق، حتى تلك التي يتم الحصول عليها بدون وصفة طبية أو الأدوية العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم تناول الأدوية المذكورة في القائمة الآتية أثناء دورة علاجك بفيفند:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيرفينادين (يُستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أستيميزول (يُستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (يُستخدم لعلاج مشكلات المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد (يُستخدم لعلاج الأمراض العقلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (يستخدم لعلاج ضربات القلب غير المنتظمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفابرادين (يُستخدم لعلاج أعراض فشل القلب المزمن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرينز (يُستخدم لعلاج فيروس نقص المناعة البشرية (HIV)) بجرعات تبلغ ٤٠٠ ملجم فأكثر مرة واحدة يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (يستخدم لعلاج النوبات)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (يُستخدم لعلاج الأرق الشديد والنوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الإرجوت (على سبيل المثال: إرجوتامين، وثنائي هيدروإرجوتامين؛ يُستخدما لعلاج الصداع النصفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس (يُستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يُستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات تبلغ ٤٠٠ ملجم فأكثر مرتين يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (مكمل عشبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نالوكسيجول: (يُستخدم لعلاج الإمساك، خاصة الناتج عن أدوية تخفيف الألم التي تسمى الأفيونات (مثل مورفين، أوكسيكودون، فينتانيل، ترامادول، كودين))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولفابتان (يُستخدم لعلاج نقص صوديوم الدم (انخفاض مستويات الصوديوم في دمك) أو لإبطاء تدهور وظائف الكلى لدى المرضى المصابين بمرض الكلى متعددة الكيسات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوراسيدون (يُستخدم لعلاج الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوكلاكس (يُستخدم لعلاج المرضى بابيضاض الدم الليمفاوي المزمن (CLL))</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال فيفند</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول فيفند:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بتفاعل حساسية تجاه أي من الأدوية الآزولية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني، أو عانيت في السابق، من مرض كبدي. إذا كنت مُصابًا بمرض كبدي، فقد يقوم طبيبك بوصف جرعة أقل من فيفند. ينبغي على طبيبك أيضًا مراقبة وظائف كبدك أثناء خضوعك للعلاج بفيفند عن طريق إجراء فحوصات للدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان معلومًا أنك مصاب باعتلال عضلة القلب أو تعاني من ضربات قلب غير منتظمة أو معدل نبضات قلب بطيء أو خلل بمخطط كهربية القلب (ECG) يُسمى &quot;مُتلازمة إطالة فترة الـQT&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي عليك تجنب ضوء الشمس والتعرض لأشعة الشمس أثناء فترة علاجك. تتزايد فرصة الإصابة بسمية الجلد أثناء تناول فيفند. وقد يحدث هذا مع تناول أدوية أخرى مثل ميثوتريكسات أو من دون. من المهم تغطية مناطق الجلد المُعرَّضة للشمس واستخدام واقٍ من الشمس ذي عامل حماية (SPF) عالٍ؛ إذ يمكن حدوث زيادة في حساسية الجلد لأشعة الشمس فوق البنفسجية. قد يتزايد حدوث هذا بسبب أدوية أخرى تسبب حساسية الجلد لضوء الشمس، مثل ميثوتريكسات. تنطبق هذه التحذيرات أيضًا على الأطفال.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">أثناء الخضوع للعلاج بفيفند:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك على الفور إذا ظهر عليك أي مما يلي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق الشمس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو بثور شديدة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العظم</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُصبت بأي من اضطرابات الجلد المذكورة أعلاه، فقد يحيلك طبيبك إلى طبيب أمراض جلدية، والذي قد يقرر بعد الاستشارة أنه من المهم تكرار خضوعك للفحص بشكلٍ منتظم. هناك فرصة ضئيلة لإصابتك بسرطان الجلد عند الاستخدام طويل الأمد لفيفند<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت عليك علامات &quot;قصور الغدة الكظرية&quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض الهرمونات الستيرويدية مثل الكورتيزول، مما قد يؤدي إلى أعراض مثل: الإرهاق المزمن أو طويل الأمد، ضعف العضلات، فقدان الشهية، فقدان الوزن، ألم البطن، يرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت عليك علامات &quot;متلازمة كوشينج&quot; حيث ينتج الجسم كمية أكبر من اللازم من هرمون الكورتيزول مما قد يؤدي إلى أعراض مثل: زيادة الوزن، ظهور كتلة دهنية بين الكتفين، استدارة الوجه، اسمرار الجلد على البطن والفخذين والثديين والذراعين، ترقق الجلد، سهولة التكدم، ارتفاع مستوى سكر الدم، فرط نمو الشعر، التعرق المفرط، يُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على طبيبك مراقبة وظائف كبدك وكليتيك عن طريق إجراء فحوصات للدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ينبغي عدم إعطاء فيفند للأطفال الذين تقل أعمارهم عن عامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك تلك التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية، عند تناولها بالتزامن مع فيفند، على آلية عمل فيفند أو قد يؤثر فيفند على آلية عملها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول الدواء التالي، إذ ينبغي تجنب استعمال فيفند في نفس الوقت إن أمكن:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يُستخدم لعلاج فيروس نقص المناعة البشرية) بجرعة قدرها ١٠٠ ملجم مرتين يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلاسديجيب (يُستخدم لعلاج السرطان) &ndash; إذا احتجت إلى استخدام كلا العقارين، فسيراقب طبيبك نظم قلبك بصفة متكررة</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًا من الدوائين التاليين، حيث ينبغي تجنب استعمال فيفند في نفس الوقت إن أمكن، ويمكن أن تكون هناك حاجة لتعديل جرعة فوريكونازول:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين (يستخدم لعلاج السل). إذا كنت تخضع بالفعل لعلاج بريفابوتين، فستكون هناك حاجة لمراقبة تعداد عناصر الدم لديك والآثار الجانبية لريفابوتين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فنيتوين (يستخدم لعلاج الصرع). إذا كنت تخضع بالفعل للعلاج بفنيتوين، فستكون هناك حاجة لمراقبة تركيز فنيتوين في الدم أثناء علاجك بفيفند وقد يتم تعديل جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًا من الأدوية التالية؛ إذ قد تكون هناك حاجة لتعديل الجرعة أو الخضوع للمراقبة للتحقق من أن الأدوية و/أو فيفند لا يزال يحدث التأثير المرغوب فيه:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين ومضادات التجلط الأخرى (مثل فينوبروكومون، أسينوكومارول؛ يستخدما لإبطاء معدل تجلط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يُستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (يُستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية السلفونيليوريا (مثل، تولبوتاميد، وجليبيزيد، وجليبوريد) (تستخدم لعلاج داء السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (مثل: أتورفاستاتين، سيمفاستاتين) (تستخدم لخفض الكوليسترول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازيبينات (على سبيل المثال، ميدازولام، تريازولام) (تستخدم لعلاج الأرق والتوتر الشديدين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوميبرازول (يستخدم لعلاج القرح)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل التي تؤخذ عن طريق الفم (إذا تناولتِ فيفند أثناء استخدام موانع الحمل التي تؤخذ عن طريق الفم، فقد تحدث لكِ آثار جانبية مثل الغثيان واضطرابات الحيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الفينكا (مثل، فينكريستين، وفينبلاستين) (تستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات كيناز التيروزين (مثل أكسيتينيب، بوسوتينيب، كابوزانتينيب، سيريتينيب، كوبيميتينيب، دابرافينيب، داساتينيب، نيلوتينيب، سونيتينيب، إيبروتينيب، ريبوسيكليب) (تستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريتينوين (يستخدم لعلاج ابيضاض الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندينافير والمثبطات الأخرى لإنزيم بروتياز فيروس نقص المناعة البشرية (تستخدم لعلاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المثبطات غير النيكليوزيدية لإنزيم المنتسخة العكسية (مثل، إيفافيرينز، وديلافيردين، ونيفيرابين) (تستخدم لعلاج فيروس نقص المناعة البشرية) (بعض جرعات إيفافيرينز لا يمكن تناولها في نفس الوقت مع فيفند)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثادون (يستخدم لعلاج إدمان الهيروين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل وفينتانيل والمستحضرات الأفيونية قصيرة المفعول الأخرى مثل سوفينتانيل (مسكنات الألم التي تستخدم في الإجراءات الجراحية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسيكودون والمستحضرات الأفيونية ممتدة المفعول الأخرى مثل هيدروكودون (تستخدم في تسكين الآلام المتوسطة إلى الشديدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (مثل: إيبوبروفين، ديكلوفيناك) (تستخدم لعلاج الألم والالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول (يستخدم لعلاج العدوى الفطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفروليموس (يستخدم لعلاج سرطان الكلى المتقدم ولمرضى زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليتيرموفير (يستخدم لمنع الإصابة بمرض الفيروس المضخم للخلايا (CMV) بعد عملية زرع نخاع العظم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكافتور: يستخدم لعلاج التليف الكيسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكلوكساسلين (مضاد حيوي يستخدم لعلاج حالات العدوى البكتيرية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">يجب عدم تناول فيفند أثناء الحمل، إلّا إذا أشار طبيبكِ بذلك. يجب على السيدات القادرات على الإنجاب استخدام وسيلة فعالة لمنع الحمل. اتصلي بطبيبكِ فورًا إذا أصبحتِ حاملًا أثناء تناولك لفيفند.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير فيفند على القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن لفيفند أن يسبب تغيمًا في الرؤية أو حساسية غير مريحة تجاه الضوء. لا تقم بالقيادة أو تشغيل أي أدوات أو آلات عندما تكون تحت تأثير الدواء. قم بالاتصال بطبيبك إذا أصبت بهذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات فيفند</strong></p><p dir="RTL"><strong>يحتوي فيفند على السكروز</strong></p><p dir="RTL">يحتوي هذا الدواء على ٠.٥٤ جم من السكروز لكل مل من المستعلق. إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض السكريات، فاتصل به قبل تناول فيفند. ينبغي مراعاة ذلك مع المرضى المصابين بداء السكري. قد يكون مضرًا للأسنان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فيفند على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل ٥ مل من المستعلق، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فيفند على ملح</strong><strong> </strong><strong>البنزوات</strong><strong>/</strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ١٢ ملجم من ملح البنزوات لكل جرعة قدرها ٥ ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بتحديد جرعتك اعتمادًا على وزنك ونوع العدوى المُصاب بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها للبالغين (بما في ذلك المرضى المسنين) هي كالآتي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td colspan="2"><p dir="RTL"><strong>المستعلق الذي </strong><strong>يؤخذ عن طريق الفم</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">المرضى ممن يزنون ٤٠ كلجم وأكثر</p></td><td><p dir="RTL">المرضى أقل من ٤٠ كلجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة لأول ٢٤ ساعة</strong><strong> </strong></p><p dir="RTL">(جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">١٠ مل (٤٠٠ ملجم) كل ١٢ ساعة لأول ٢٤ ساعة</p></td><td style="vertical-align:top"><p dir="RTL">٥ مل (٢٠٠ ملجم) كل ١٢ ساعة لأول ٢٤ ساعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة بعد أول ٢٤ ساعة</strong> (جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">٥ مل (٢٠٠ ملجم) مرتين في اليوم</p></td><td style="vertical-align:top"><p dir="RTL">٢٫٥ مل (١٠٠ ملجم) مرتين في اليوم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">ووفقًا لاستجابتك للعلاج، قد يزيد طبيبك الجرعة اليومية إلى ٧٫٥ مل (٣٠٠ ملجم) مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر الطبيب خفض الجرعة إذا كنت مُصابًا بتليف خفيف إلى متوسط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">الجرعة الموصى بها للأطفال والمراهقين هي كالآتي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td colspan="2"><p dir="RTL"><strong>المستعلق الذي </strong><strong>يؤخذ عن طريق الفم</strong><strong> </strong></p></td></tr><tr><td><p dir="RTL">الأطفال من سن عامين وحتى أقل من ١٢ عامًا والمراهقون من سن ١٢ إلى ١٤ عامًا ويزنون أقل من ٥٠ كلجم</p></td><td><p dir="RTL">المراهقون من سن ١٢ وحتى ١٤ عامًا ويزنون ٥٠ كلجم أو أكثر؛ وجميع المراهقين الأكبر من ١٤ عامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة لأول ٢٤ ساعة </strong></p><p dir="RTL">(جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">سيبدأ علاجك في صورة تسريب</p></td><td style="vertical-align:top"><p dir="RTL">١٠ مل (٤٠٠ ملجم) كل ١٢ ساعة لأول ٢٤ ساعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة بعد أول ٢٤ ساعة </strong></p><p dir="RTL">(جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">٠٫٢٢٥ مل/كلجم (٩ ملجم/كلجم) مرتين في اليوم</p><p dir="RTL">]بحدٍ أقصى للجرعة ٨٫٧٥ مل (٣٥٠ ملجم) مرتين يوميًا[</p></td><td style="vertical-align:top"><p dir="RTL">٥ مل (٢٠٠ ملجم) مرتين في اليوم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">ووفقًا لاستجابتك للعلاج، قد يزيد طبيبك الجرعة اليومية أو يخفضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول مستعلقك قبل تناول وجبتك بساعة واحدة على الأقل أو بعد تناولها بساعتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت أنت أو طفلك تتناولان فيفند لمنع حالات العدوى الفطرية، فقد يقوم طبيبك بإيقاف إعطائك فيفند إذا تعرضت أنت أو طفلك لآثار جانبية ذات صلة بالعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم مزج مستعلق فيفند مع أي دواء آخر. ينبغي عدم إجراء تخفيف إضافي للمستعلق بالماء أو بأية سوائل أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات إعداد المستعلق: </strong></p><p dir="RTL"><strong>ينصح بأن يقوم الصيدلي الذي تتعامل معه بإعداد مستعلق فيفند قبل أن يعطيه لك.</strong> يكون مستعلق فيفند جاهزًا للاستخدام عندما يصبح في صورة سائلة. إذا كان الدواء في شكل مسحوق جاف، ينبغي عليك إعداد المستعلق الفموي باتباع التعليمات أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">١.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقر على الزجاجة حتى يتحرر المسحوق.</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الغطاء.</p><p dir="RTL">٣.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أضف كأسي قياس (كأس القياس مرفق في العبوة الكرتونية) من الماء (بإجمالي ٤٦ مل) إلى الزجاجة. قم بملء كأس القياس حتى الخط الموضح، ثم اسكب الماء في الزجاجة. ينبغي أن تقوم دائمًا بإضافة كمية إجمالية من الماء تبلغ ٤٦ مل بغض النظر إلى الجرعة التي تتناولها.</p><p dir="RTL">٤.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع الغطاء من جديد ورج الزجاجة بقوة لمدة حوالى دقيقة. بعد التحضير، يجب أن يكون الحجم الكلي للمستعلق ٧٥ مل.</p><p dir="RTL">٥.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الغطاء. اغرس مهايئ الزجاجة في العنق (كما هو مبين بالشكل أدناه). يتم توفير المهايئ حتى تتمكن من ملء المحقنة المخصصة للتناول عن طريق الفم بالدواء من الزجاجة. أعد الغطاء على الزجاجة.</p><p dir="RTL">٦.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتب تاريخ انتهاء صلاحية المستعلق الذي تم تحضيره على ملصق الزجاجة (مدة صلاحية المستعلق الذي يتم تحضيره هي ١٤ يومًا). ينبغي التخلص من أي مستعلق غير مستخدم بعد هذا التاريخ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
   id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1032"
   type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
   margin-left:-4.25pt;margin-top:72.05pt;width:41.25pt;height:21.75pt;
   text-indent:0;z-index:251663360;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Times New Roman",serif'>الزجاجة<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="57" height="31" alt="Text Box: الزجاجة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:-2.95pt;
   margin-top:37.9pt;width:42.55pt;height:34pt;text-indent:0;z-index:251662336;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Times New Roman",serif'>غطاء الزجاجة<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="60" height="48" alt="Text Box: غطاء الزجاجة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1030" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:126.7pt;
   margin-top:74.55pt;width:32.5pt;height:31.3pt;text-indent:0;z-index:251664384;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:10.0pt;font-family:"Times New Roman",serif'><span
      dir=RTL></span>٢٣ مل<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="46" height="45" alt="Text Box: ٢٣ مل" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1029" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:128.35pt;
   margin-top:21.9pt;width:27.8pt;height:31.3pt;text-indent:0;z-index:251665408;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:10.0pt;font-family:"Times New Roman",serif'><span
      dir=RTL></span>٢٣ مل<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="40" height="44" alt="Text Box: ٢٣ مل" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_7" o:spid="_x0000_s1028" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:267.35pt;
   margin-top:71.25pt;width:42.25pt;height:21.75pt;text-indent:0;z-index:251661312;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Times New Roman",serif'>الزجاجة<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="59" height="32" alt="Text Box: الزجاجة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_6" o:spid="_x0000_s1027" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:268.15pt;
   margin-top:42.2pt;width:43.2pt;height:30.4pt;text-indent:0;z-index:251660288;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Times New Roman",serif'>مهايئ الزجاجة<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="60" height="43" alt="Text Box: مهايئ الزجاجة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1026" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:267.1pt;
   margin-top:1.25pt;width:50.65pt;height:48.25pt;text-indent:0;z-index:251659264;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Times New Roman",serif'>محقنة للتناول عن طريق الفم<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="70" height="67" alt="Text Box: محقنة للتناول عن طريق الفم" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_17" o:spid="_x0000_i1026" type="#_x0000_t75"
   style='width:310.5pt;height:125pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png"
    o:title="" croptop=".25" cropbottom="16924f" cropleft="9738f" cropright="12891f"/>
  </v:shape><![endif]--><img width="414" height="167" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png" /></p><p dir="RTL"><strong>تعليمات الاستخدام: </strong></p><p dir="RTL">ينبغي على الصيدلي أن يشرح لك كيف تقيس الدواء بواسطة المحقنة متعددة الجرعات المستخدمة للتناول عن طريق الفم والمتوفرة داخل العبوة. يرجى قراءة التعليمات أدناه قبل استخدام مستعلق فيفند.</p><p dir="RTL">&nbsp;</p><p dir="RTL">١.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رج زجاجة المستعلق الذي تم تحضيره المغلقة لمدة حوالى ١٠ ثوانٍ قبل الاستخدام. انزع الغطاء.</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل طرف المحقنة الخاصة بالتناول عن طريق الفم في المهايئ مع مراعاة أن تكون الزجاجة في وضع أفقي على سطح مستوٍ.</p><p dir="RTL">٣.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة مع تثبيت المحقنة الخاصة بالتناول عن طريق الفم في مكانها. اسحب مكبس المحقنة الخاصة بالتناول عن طريق الفم ببطء حتى تصل إلى علامة التدريج التي تحدد الجرعة التي يجب أن تتناولها.</p><p dir="RTL">٤.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما رأيت فقاعات كبيرة، اضغط على المكبس ببطء إلى داخل المحقنة. سيدفع ذلك الدواء مجددًا إلى داخل الزجاجة. كرر الخطوة رقم ٣ مرة أخرى.&nbsp;</p><p dir="RTL">٥.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة مرة أخرى، مع تثبيت المحقنة المخصصة للتناول عن طريق الفم في مكانها. أخرِج المحقنة المخصصة للتناول عن طريق الفم من الزجاجة.</p><p dir="RTL">٦.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع طرف المحقنة المخصصة للتناول عن طريق الفم داخل الفم. وجّه طرف المحقنة المخصصة للتناول عن طريق الفم نحو الجهة الداخلية من الخد. اضغط على مكبس المحقنة المخصصة للتناول عن طريق الفم ببطء. لا تقم بضخ الدواء بسرعة. إذا كان الدواء سيُعطى لطفل، تأكد من أن الطفل جالس أو مثبت في وضع مستقيم قبل إعطائه الدواء.</p><p dir="RTL">٧.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعِد وضع الغطاء على الزجاجة، مع ترك مهايئ الزجاجة في مكانه. اغسل المحقنة المخصصة للتناول عن طريق الفم وفقًا للتعليمات الواردة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_18" o:spid="_x0000_i1025"
   type="#_x0000_t75" style='width:313.5pt;height:98pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="418" height="131" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.jpg" /></p><p dir="RTL">٦&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٣/٤ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; ٢&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ١</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تنظيف وتخزين المحقنة: </strong></p><p dir="RTL">١.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي غسل المحقنة بعد كل جرعة. اسحب المكبس من المحقنة واغسل الجزأين بالماء الدافئ والصابون. ثم اغسلهما بالماء.</p><p dir="RTL">٢.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتجفيف الجزأين. اضغط على المكبس مجددًا لإعادته إلى المحقنة. احتفظ بالمحقنة مع الدواء في مكان نظيف وآمن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الزائدة من فيفند</strong></p><p dir="RTL">إذا أخذت كمية أكبر من المستعلق عن الكمية الموصوفة (أو إذا تناول أحد آخر المستعلق الخاص بك)، يجب عليك الحصول على الاستشارة الطبية أو الذهاب إلى قسم الإصابات بأقرب مستشفى على الفور. قم بأخذ زجاجة مستعلق فيفند الخاصة بك معك. قد تشعر بعدم تحمل للضوء بشكل غير طبيعي نتيجةً لتناول فيفند بكمية أكبر مما ينبغي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة فيفند</strong></p><p dir="RTL">من المهم تناول مستعلق فيفند بانتظام في نفس التوقيت كل يوم. إذا نسيت تناول إحدى الجرعات، فتناول جرعتك التالية عندما يحين موعدها. لا تتناول جرعة مزدوجة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول فيفند</strong></p><p dir="RTL">ثبت أن تناول جميع الجرعات في مواعيدها الصحيحة يزيد بصورة كبيرة من فعالية الدواء. لذا فمن المهم أن تستمر في تناول فيفند بصورةٍ صحيحة، كما هو مذكور أعلاه، إلّا إذا أمرك طبيبك بإيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في تناول فيفند حتى يخبرك طبيبك بالتوقف. لا توقف علاجك مبكرًا؛ إذ قد يؤدي ذلك إلى عدم شفائك من العدوى. قد يحتاج المرضى الذين يعانون من ضعف في جهاز المناعة أو المصابون بحالات عدوى شديدة إلى علاج طويل الأمد لمنع عودة العدوى مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المفترض ألّا تواجه أي آثار عندما يتم إيقاف العلاج بفيفند من قِبل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدثت أي آثار جانبية، فسيكون أغلبها على الأرجح بسيطًا ومؤقتًا. ولكن، قد يكون بعضها خطيرًا ويحتاج إلى رعاية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة &ndash; توقف عن تناول فيفند واذهب إلى أحد الأطباء على الفور</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان؛ تغير في نتائج فحوصات الدم لوظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل بصري (تغير في الرؤية بما في ذلك تغيم الرؤية، تبدلات في الألوان المرئية، عدم تحمل &nbsp; غير طبيعي للإدراك البصري للضوء، عمى الألوان، اضطراب العينين، رؤية الهالة، العمى الليلي، تأرجح الرؤية، رؤية شرر، هالة بصرية، انخفاض الحدة البصرية، سطوع الرؤية، فقدان جزء من حقل الرؤية المعتادظهور بقع أمام العينين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء، الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية، التهاب اللثة، القشعريرة، الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد بعض أنواع، بما في ذلك انخفاض شديد، خلايا الدم الحمراء (ذات صلة بالمناعة في بعض الأحيان) و/أو البيضاء (يصاحبها حمى في بعض الأحيان)، انخفاض أعداد الخلايا التي تسمى الصفيحات الدموية والتي تساعد الدم على التخثر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم، انخفاض مستوى البوتاسيوم في الدم، انخفاض مستوى الصوديوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، الاكتئاب، الارتباك، التهيج، عدم القدرة على النوم، الهلاوس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، الرعاش أو حركات عضلية لا يمكن التحكم فيها، الشعور بالوخز أو بإحساس غير الطبيعي بالجلد، زيادة في التوتر العضلي، النعاس، الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات نظم القلب بما في ذلك سرعة شديدة في نبضات القلب، بطء شديد في نبضات القلب، الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، التهاب الوريد (والذي قد يصاحبه تكون جلطة دموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة حادة في التنفس، ألم بالصدر، تورم في الوجه (الفم والشفتين وحول العينين)، تراكم السوائل في الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك، عسر الهضم، التهاب الشفتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان، التهاب الكبد وإصابة الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات طفح جلدي قد تؤدي إلى تقرح وتقشر شديدين في الجلد يتميز بوجود منطقة مسطحة وحمراء على الجلد مغطاة ببروزات متجمعة صغيرة، احمرار الجلد</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي، وجود دم في البول، تغيرات في نتائج اختبارات الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق الشمس أو تفاعلات جلدية شديدة بعد التعرض للضوء أو الشمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بالإنفلونزا، تهيج والتهاب القناة المعدية المعوية، التهاب القناة المعدية المعوية المسبب للإسهال المرتبط بالمضادات الحيوية، التهاب الأوعية الليمفاوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب النسيج الرقيق المبطن للجدار الداخلي للبطن والمغطي لأعضاء البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليمفاوية (مؤلم في بعض الأحيان)، فشل نخاع الدم، زيادة اليوزينيات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط وظيفة الغدة الكظرية، قلة نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف دماغية غير طبيعية، أعراض مشابهة لمرض باركنسون، إصابة عصب مما يؤدي إلى الخدر، الألم، الشعور بالوخز أو الحرقة في اليدين أو القدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التوازن أو التناسق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الدماغ&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية، حالات خطيرة تصيب العين بما في ذلك: ألم والتهاب العينين والجفون، حركة غير طبيعية في العين، تلف العصب البصري الذي يؤدي إلى خلل في الرؤية، تورم القرص البصري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حساسية اللمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حس تذوق غير طبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في السمع، طنين الأذن، الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أعضاء داخلية معينة - البنكرياس والاثنا عشر، تورم والتهاب اللسان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الكبد، فشل الكبد، مرض المرارة، حصوات المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل، التهاب الأوردة تحت الجلد (والذي قد يصاحبه تكون جلطة دموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى، وجود بروتينات في البول، تلف الكلى&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل سريع للغاية لضربات القلب أو تخطي ضربات قلب، يصحبه دوافع كهربية غير منتظمة في بعض الأحيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لمخطط كهربية القلب (ECG)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات الكوليسترول في الدم، زيادة مستويات اليوريا في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (شديدة أحيانًا)، بما في ذلك الحالات الجلدية المهددة للحياة التي تسبب بثورًا وتقرحات مؤلمة في الجلد والغشاء المخاطي، خاصة في&nbsp; الفم، التهاب الجلد، الشرى، احمرار الجلد وتهيجه، تغير لون الجلد إلى الأحمر أو البنفسجي الذي قد يكون السبب فيه انخفاض تعداد الصفيحات الدموية، الإكزيما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع التسريب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية أو استجابة مناعية مبالغ فيها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة المحيطة بالعظام</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغدة الدرقية مفرطة النشاط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور وظائف المخ وهي إحدى المضاعفات الخطيرة للمرض الكبدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان معظم الألياف في العصب البصري، تغيم القرنية، حركة العين بشكل لا إرادي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية الفقاعية للضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب يقوم فيه الجهاز المناعي للجسم بمهاجمة جزء من الجهاز العصبي الطرفي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في نظم القلب أو توصيل الإشارات القلبية (تكون مهددة للحياة أحيانًا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية مهدد للحياة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظام تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (شديدة في بعض الأحيان)، بما في ذلك تورم سريع للأدمة والنسيج تحت الجلد والغشاء المخاطي والأنسجة تحت المخاطية، بقع مصحوبة بحكة أو متقرحة من جلد سميك، أحمر يصحبه قشور فضية بالجلد، تهيج الجلد والأغشية المخاطية، حالات جلدية مهددة للحياة تسبب انفصال أجزاء كبيرة من البشرة، وهي الطبقة الخارجية للجلد، عن طبقات الجلد أسفلها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع صغيرة من الجلد الجاف المصحوب بقشور، يكون في بعض الأحيان سميكًا وذو سنون مدببة أو &quot;قرون&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية التي لا يُعرف معدل تكرارها:</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمش وبقع متصبغة</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية مهمة أخرى غير معروف معدل تكرارها ولكن ينبغي عليك إبلاغ طبيبك بها على الفور:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون وجود آفات جلدية حمراء، مصحوبة ببقع بها بقشور أو على شكل حلقات عرضًا لمرض مناعة ذاتية يسمى لوباس ايريثماتوزس الجلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على طبيبك مراقبة وظائف الكبد والكلى لديك عن طريق إجراء فحوصات الدم، حيث من المعروف أن فيفند يؤثر على الكبد والكلى. يُرجى إخبار طبيبك إذا عانيت من أي آلام في المعدة أو إذا كان لبرازك درجة تماسك مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث حالات إصابة بسرطان الجلد في المرضى الذين تمت معالجتهم بفيفند لفترات طويلة من الزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعرض الأطفال بصورة أكثر تكرارًا لحروق الشمس أو تفاعلات جلدية شديدة بعد التعرض للضوء أو الشمس. إذا أُصبت أنت أو طفلك باضطرابات الجلد، فقد يحيلك طبيبك إلى طبيب أمراض جلدية، والذي قد يقرر بعد الاستشارة أنه من المهم تكرار خضوعك أو خضوع طفلك للفحص بشكلٍ منتظم. تمت ملاحظة ارتفاع إنزيمات الكبد بصورة أكثر تكرارًا أيضًا في الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استمرت أي من هذه الآثار الجانبية أو أصبحت مزعجة، يُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:398px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <u>&rlm;</u>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL"><br />لا تستخدم هذا الدواء بعد انتهاء فترة الصلاحية المُبينة على الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.<br />&nbsp;</p><p dir="RTL">مسحوق لتحضير مستعلق يؤخذ عن طريق الفم: قم بتخزينه في درجة حرارة تتراوح بين ٢ و٨ درجات مئوية (في الثلاجة) قبل التحضير.<br />بالنسبة للمستعلق الذي تم تحضيره:<br />احفظه في درجة حرارة اقل من ٣٠ درجة مئوية.<br />لا تضعه في الثلاجة ولا تجمده.<br />احفظه في الزجاجة الأصلية<br />احتفظ بالزجاجة محكمة الغلق.<br />ينبغي التخلص من أي مستعلق متبقٍ بعد ١٤ يومًا من التحضير.<br />&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي فوريكونازول. تحتوي كل زجاجة على ٤٥ جم من المسحوق الذي يعطي ٧٠ مل من المستعلق عند تحضيره بالماء، وفقا لما هو موصى به. يحتوي ١ مل من المستعلق الذي تم تحضيره على ٤٠ ملجم من فوريكونازول<strong>.</strong> (انظر القسم ٣ &quot;طريقة استخدام فيفند&quot;).</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: سكروز؛ سيليكا غروانية؛ ثاني أكسيد التيتانيوم؛ صمغ الزانثان؛ سترات الصوديوم؛ بنزوات الصوديوم؛ حمض الستريك؛ نكهة برتقال طبيعية (انظر القسم ٢؛ يحتوي فيفند ٤٠ ملجم/مل، مسحوق مخصص لتحضير مستعلق يؤخذ عن طريق الفم، على السكروز وملح البنزوات (بنزوات الصوديوم) والصوديوم).</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يتوفر فيفند في شكل مسحوق أبيض أو يميل لونه إلى البياض لتحضير مستعلق يؤخذ عن طريق الفم، مما يعطي مستعلقًا أبيض أو يميل لونه إلى البياض بنكهة البرتقال عند تحضيره بالماء.</p></td></tr></tbody></table><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">Pfizer Europe MA EEIG, Belgium، بلجيكا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة </strong></p><p dir="RTL">Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poc&eacute;-sur-Cisse, France، فرنسا.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل/نيسان ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VFEND 40 mg/ml powder for oral suspension 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of oral suspension contains 40 mg of voriconazole when reconstituted with water. 
Each bottle contains 3 g of voriconazole. 

Excipients with known effect
Each ml of suspension contains 0.54 g sucrose. 
Each ml of suspension contains 2.40 mg sodium benzoate.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for oral suspension.
White to off-white powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VFEND, is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2&nbsp;years and above as follows:</p><p>&nbsp;</p><p>Treatment of invasive aspergillosis</p><p>&nbsp;</p><p>Treatment of candidaemia in non-neutropenic patients.</p><p>&nbsp;</p><p>Treatment of fluconazole-resistant serious invasive <em>Candida</em> infections (including <em>C. krusei</em>).</p><p>&nbsp;</p><p>Treatment of serious fungal infections caused by <em>Scedosporium</em> spp. and <em>Fusarium</em> spp.</p><p>&nbsp;</p><p>VFEND should be administered primarily to patients with progressive, possibly life-threatening infections.</p><p>&nbsp;</p><p>Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4).</p><p>&nbsp;</p><p>VFEND is also available as 50&nbsp;mg and 200&nbsp;mg film-coated tablets and 200&nbsp;mg powder for solution for infusion.</p><p>&nbsp;</p><p><u>Treatment</u></p><p><em>Adults </em></p><p>Therapy must be initiated with the specified loading dose regimen of either intravenous or oral VFEND to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96%; see section 5.2), switching between intravenous and oral administration is appropriate when clinically indicated.</p><p>&nbsp;</p><p>Detailed information on dosage recommendations is provided in the following table:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Intravenous </strong></p></td><td colspan="2"><p><strong>Oral Suspension </strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients 40 kg and</p><p>above*</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Patients less than 40&nbsp;kg*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose </strong></p><p><strong>regimen </strong></p><p><strong>(first 24 hours) </strong></p></td><td style="vertical-align:top"><p>6&nbsp;mg/kg every 12 hours</p></td><td style="vertical-align:top"><p>10 ml (400&nbsp;mg) every 12&nbsp;hours</p></td><td style="vertical-align:top"><p>5 ml (200&nbsp;mg) every 12&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose </strong></p><p><strong>(after first 24 hours) </strong></p></td><td style="vertical-align:top"><p>4&nbsp;mg/kg twice daily</p></td><td style="vertical-align:top"><p>5 ml (200&nbsp;mg) twice</p><p>daily</p></td><td style="vertical-align:top"><p>2.5 ml (100&nbsp;mg) twice daily</p></td></tr></tbody></table><p>* This also applies to patients aged 15 years and older</p><p>&nbsp;</p><p><em><u>Duration of treatment </u></em></p><p>Treatment duration should be as short as possible depending on the patient&rsquo;s clinical and mycological response. Long term exposure to voriconazole greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Adults)</u></em></p><p>If patient response to treatment is inadequate, the maintenance dose may be increased to 7.5 ml (300&nbsp;mg) twice daily for oral administration. For patients less than 40&nbsp;kg the oral dose may be increased to 3.75 ml (150&nbsp;mg) twice daily.</p><p>&nbsp;</p><p>If patient is unable to tolerate treatment at a higher dose, reduce the oral dose by 1.25 ml (50 mg) steps to the 5 ml (200&nbsp;mg) twice daily [or 2.5 ml (100&nbsp;mg) twice daily for patients less than 40&nbsp;kg] maintenance dose.</p><p>&nbsp;</p><p>In case of use as prophylaxis, refer below.</p><p>&nbsp;</p><p><em>Children (2 to &lt;12 years) and young adolescents with low body weight (12 to 14 years and &lt;50&nbsp;kg)</em></p><p>Voriconazole should be dosed as children as these young adolescents may metabolise voriconazole more similarly to children than to adults.</p><p>&nbsp;</p><p>The recommended dosing regimen is as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Intravenous </strong></p></td><td><p><strong>Oral Suspension</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading Dose Regimen</strong></p><p><strong>(first 24 hours)</strong></p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg every 12 hours</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td><p><strong>Maintenance Dose</strong></p><p><strong>(after first 24 hours)</strong></p></td><td><p>8&nbsp;mg/kg twice daily</p></td><td style="vertical-align:top"><p>0.225 ml/kg (9&nbsp;mg/kg) twice daily<br />[a maximum dose of 8.75 ml (350&nbsp;mg) twice daily]</p></td></tr></tbody></table><p>Note:&nbsp; Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescents aged 12 to &lt;17 years.</p><p>&nbsp;</p><p>It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8&nbsp;mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9&nbsp;mg/kg oral dose.</p><p>&nbsp;</p><p>These oral dose recommendations for children are based on studies in which voriconazole was administered as the powder for oral suspension. Bioequivalence between the powder for oral suspension and tablets has not been investigated in a paediatric population. Considering the assumed limited gastro-enteric transit time in paediatric patients, the absorption of tablets may be different in paediatric compared to adult patients. It is therefore recommended to use the oral suspension formulation in children aged 2 to &lt;12.</p><p>&nbsp;</p><p><em>All other adolescents (12 to 14 years and &ge;50 kg; 15 to 17 years regardless of body weight)</em></p><p>Voriconazole should be dosed as adults.</p><p>&nbsp;</p><p><em><u>Dosage adjustment </u></em><em><u>[</u></em><em><u>Children </u></em><em><u>(</u></em><em><u>2 to &lt;12 years</u></em><em><u>)</u></em><em><u> and young adolescents with low body weight </u></em><em><u>(</u></em><em><u>12 to 14 years and &lt;50&nbsp;kg</u></em><em><u>)]</u></em></p><p>If patient response to treatment is inadequate, the dose may be increased by 0.025 ml/kg (1&nbsp;mg/kg) steps [or by 1.25 ml (50&nbsp;mg) steps if the maximum oral dose of 8.75 ml (350&nbsp;mg) was used initially]. If patient is unable to tolerate treatment, reduce the dose by 0.025 ml/kg (1&nbsp;mg/kg) steps [or by 1.25 ml (50&nbsp;mg) steps if the maximum oral dose of 8.75 ml (350&nbsp;mg) was used initially].</p><p>&nbsp;</p><p>Use in paediatric patients aged 2 to &lt;12 years with hepatic or renal insufficiency has not been studied (see sections 4.8 and 5.2).</p><p>&nbsp;</p><p><u>Prophylaxis in Adults and Children</u></p><p>Prophylaxis should be initiated on the day of transplant and may be administered for up to 100&nbsp;days. Prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (IFI) as defined by neutropenia or immunosuppression. It may only be continued up to 180 days after transplantation in case of continuing immunosuppression or graft versus host disease (GvHD) (see section 5.1).</p><p>&nbsp;</p><p><em>Dosage </em></p><p>The recommended dosing regimen for prophylaxis is the same as for treatment in the respective age groups. Please refer to the treatment tables above.</p><p>&nbsp;</p><p><em>Duration of prophylaxis</em></p><p>The safety and efficacy of voriconazole use for longer than 180 days has not been adequately studied in clinical trials.</p><p>&nbsp;</p><p>Use of voriconazole in prophylaxis for greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>The following instructions apply to both Treatment and Prophylaxis</u></p><p>&nbsp;</p><p><em>Dosage adjustment</em></p><p>For prophylaxis use, dose adjustments are not recommended in the case of lack of efficacy or treatment‑related adverse events. In the case of treatment-related adverse events, discontinuation of voriconazole and use of alternative antifungal agents must be considered (see sections 4.4 and 4.8)</p><p>&nbsp;</p><p><em><u>Dosage adjustments in case of coadministration</u></em></p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased from 5 ml (200&nbsp;mg) to 10 ml (400&nbsp;mg) orally, twice daily [2.5 ml (100&nbsp;mg) to 5 ml (200&nbsp;mg) orally, twice daily in patients less than 40&nbsp;kg], see sections 4.4 and 4.5.</p><p>&nbsp;</p><p>The combination of voriconazole with rifabutin should, if possible be avoided. However, if the combination is strictly needed, the maintenance dose of voriconazole may be increased from 5 ml (200&nbsp;mg) to 8.75&nbsp;ml (350&nbsp;mg) orally, twice daily [2.5 ml (100&nbsp;mg) to 5 ml (200&nbsp;mg) orally, twice daily in patients less than 40&nbsp;kg], see sections 4.4 and 4.5.</p><p>&nbsp;</p><p>Efavirenz may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 10 ml (400&nbsp;mg) every 12 hours and the efavirenz dose is reduced by 50%, i.e. to 300&nbsp;mg once daily. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The pharmacokinetics of orally administered voriconazole are not affected by renal impairment. Therefore, no adjustment is necessary for oral dosing for patients with mild to severe renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121&nbsp;ml/min. A 4-hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p><p><u>&nbsp;</u></p><p><em><u>Hepatic impairment</u></em></p><p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C).</p><p>&nbsp;</p><p>There is limited data on the safety of VFEND in patients with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin &gt;5&nbsp;times the upper limit of normal).</p><p>&nbsp;</p><p>Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity (see section&nbsp;4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of VFEND in children below 2 years has not been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>VFEND oral suspension is to be taken at least one hour before, or two hours following, a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide, quinidine or ivabradine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.5). 

Coadministration with rifampicin, carbamazepine, phenobarbital and St John’s Wort since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see section 4.5). 

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see section 4.5, for lower doses see section 4.4).

Coadministration with high-dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose (see section 4.5, for lower doses see section 4.4). 

Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism (see section 4.5). 

Coadministration with sirolimus since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5). 

Coadministration of voriconazole with naloxegol, a CYP3A4 substrate, since increased plasma concentrations of naloxegol can precipitate opioid withdrawal symptoms (see section 4.5).

Coadministration of voriconazole with tolvaptan since strong CYP3A4 inhibitors such as voriconazole significantly increase plasma concentrations of tolvaptan (see section 4.5).

Coadministration of voriconazole with lurasidone since significant increases in lurasidone exposure have the potential for serious adverse reactions (see section 4.5).

Coadministration with venetoclax at initiation and during venetoclax dose titration phase since voriconazole is likely to significantly increase plasma concentrations of venetoclax and increase risk of tumour lysis syndrome (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Caution should be used in prescribing VFEND to patients with hypersensitivity to other azoles (see also section 4.8).</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>Voriconazole has been associated with QTc interval prolongation. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory. Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc prolongation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, in particular when heart failure is present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant medicinal product that is known to prolong QTc interval. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2). A study has been conducted in healthy volunteers which examined the effect on QTc interval of single doses of voriconazole up to 4 times the usual daily dose. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500&nbsp;msec (see section 5.1).</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>In clinical trials, there have been cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy). Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of hepatic function</u></p><p>Patients receiving VFEND must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with VFEND and at least weekly for the first month of treatment. Treatment duration should be as short as possible; however, if based on the benefit-risk assessment the treatment is continued (see section 4.2), monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.</p><p>&nbsp;</p><p>If the liver function tests become markedly elevated, VFEND should be discontinued, unless the medical judgment of the risk-benefit of the treatment for the patient justifies continued use.</p><p>&nbsp;</p><p>Monitoring of hepatic function should be carried out in both children and adults.</p><p>&nbsp;</p><p><u>Serious dermatological adverse reactions</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Phototoxicity</u></p><p>In addition VFEND has been associated with phototoxicity including reactions such as ephelides, lentigo, actinic keratosis and pseudoporphyria. There is a potential increased risk of skin reactions/toxicity with concomitant use of photosensitising agents (e.g., methotrexate, etc). It is recommended that all patients, including children, avoid exposure to direct sunlight during VFEND treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF). In addition, VFEND has been associated with photosensitivity related skin reactions such as cheilitis, and cutaneous lupus erythematosus, as well as increased risk of skin toxicity with concomitant use of methotrexate, a drug associated with ultraviolet (UV) reactivation. There is the potential for this risk to be observed with other drugs associated with UV reactivation.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Squamous cell carcinoma of the skin (SCC)</u></p><p>Squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in patients, some of whom have reported prior phototoxic reactions. If phototoxic reactions occur multidisciplinary advice should be sought, VFEND discontinuation and use of alternative antifungal agents should be considered and the patient should be referred to a dermatologist. If VFEND is continued, however, dermatologic evaluation should be performed on a systematic and regular basis, to allow early detection and management of premalignant lesions. VFEND should be discontinued if premalignant skin lesions or squamous cell carcinoma are identified (see below the section under Long-term treatment).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported with the use of voriconazole. If a patient develops a rash he should be monitored closely and VFEND discontinued if lesions progress.</p><p>&nbsp;</p><p><u>Adrenal events</u></p><p>Reversible cases of adrenal insufficiency have been reported in patients receiving azoles, including voriconazole. Adrenal insufficiency has been reported in patients receiving azoles with or without concomitant corticosteroids. In patients receiving azoles without corticosteroids, adrenal insufficiency is related to direct inhibition of steroidogenesis by azoles. In patients taking corticosteroids, voriconazole associated CYP3A4 inhibition of their metabolism may lead to corticosteroid excess and adrenal suppression (see section 4.5). Cushing&rsquo;s syndrome with and without subsequent adrenal insufficiency has also been reported in patients receiving voriconazole concomitantly with corticosteroids.</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued (see section 4.5). Patients should be instructed to seek immediate medical care if they develop signs and symptoms of Cushing&rsquo;s syndrome or adrenal insufficiency.</p><p>&nbsp;</p><p><u>Long-term treatment</u></p><p>Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to VFEND (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p>Squamous cell carcinoma of the skin (SCC) (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in relation with long-term VFEND treatment (see section 4.8).</p><p>&nbsp;</p><p>Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels has been reported in transplant patients. If a patient develops skeletal pain and radiologic findings compatible with periostitis VFEND discontinuation should be considered after multidisciplinary advice (see section 4.8).</p><p>&nbsp;</p><p><u>Visual adverse reactions</u></p><p>There have been reports of prolonged visual adverse reactions, including blurred vision, optic neuritis and papilloedema (see section 4.8).</p><p>&nbsp;</p><p><u>Renal adverse reactions</u></p><p>Acute renal failure has been observed in severely ill patients undergoing treatment with VFEND. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medicinal products and have concurrent conditions that may result in decreased renal function (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p><p>&nbsp;</p><p><u>Monitoring of pancreatic function</u></p><p>Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during VFEND treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and effectiveness in paediatric subjects below the age of two years has not been established (see sections 4.8 and 5.1). Voriconazole is indicated for paediatric patients aged two years or older. A higher frequency of liver enzyme elevations was observed in the paediatric population (see section 4.8). Hepatic function should be monitored in both children and adults. Oral bioavailability may be limited in paediatric patients aged 2 to &lt;12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Serious dermatological adverse reactions (including SCC)</u></p><p>The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photoprotection are warranted in this population of patients. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.</p><p>&nbsp;</p><p><u>Prophylaxis</u></p><p>In case of treatment-related adverse events (hepatotoxicity, severe skin reactions including phototoxicity and SCC, severe or prolonged visual disorders and periostitis), discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p><u>Phenytoin (CYP2C9 substrate and potent CYP450 inducer)</u></p><p>Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate</u>)</p><p>When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400&nbsp;mg every 12 hours and the dose of efavirenz should be decreased to 300&nbsp;mg every 24 hours (see sections 4.2, 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Glasdegib<strong> </strong>(CYP3A4 substrate)</u></p><p>Coadministration of voriconazole is expected to increase glasdegib plasma concentrations and increase the risk of QTc prolongation (see section 4.5). If concomitant use cannot be avoided, frequent ECG monitoring is recommended.</p><p>&nbsp;</p><p><u>Tyrosine kinase inhibitors (CYP3A4 substrate)</u></p><p>Coadministration of voriconazole with tyrosine kinase inhibitors metabolised by CYP3A4 is expected to increase tyrosine kinase inhibitor plasma concentrations and the risk of adverse reactions. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor and close clinical monitoring is recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Rifabutin (potent CYP450 inducer)</u></p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole. Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>Coadministration of voriconazole and low-dose ritonavir (100&nbsp;mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Everolimus </u><u>(CYP3A4 substrate, P-gp substrate)</u></p><p>Coadministration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation (see section 4.5).</p><p>&nbsp;</p><p><u>Methadone (CYP3A4 substrate)</u></p><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when coadministered with voriconazole since methadone levels increased following coadministration of voriconazole. Dose reduction of methadone may be needed (see section 4.5).</p><p>&nbsp;</p><p><u>Short-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole (see section 4.5). As the half-life of alfentanil is prolonged in a 4-fold manner when alfentanil is coadministered with voriconazole, and in an independent published study concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC<sub>0-&infin;</sub> of fentanyl, frequent monitoring for opiate‑associated adverse reactions (including a longer respiratory monitoring period) may be necessary.</p><p><u>&nbsp;</u></p><p><u>Long-acting opiates </u><u>(CYP3A4 substrate)</u></p><p>Reduction in the dose of oxycodone and other long-acting opiates metabolised by CYP3A4 (e.g., hydrocodone) should be considered when coadministered with voriconazole. Frequent monitoring for opiate‑associated adverse reactions may be necessary (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Fluconazole<em> </em>(CYP2C9, CYP2C19 and CYP3A4 inhibitor)</u></p><p>Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in C<sub>max</sub> and AUC<sub>&tau; </sub>of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole‑associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Excipients</u></p><p>&nbsp;</p><p><em><u>Sucrose</u></em></p><p>This medicinal product contains 0.54 g sucrose per ml. This should be taken into account in patients with diabetes mellitus. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. May be harmful to the teeth.</p><p>&nbsp;</p><p><em><u>Sodium</u></em></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 5&nbsp;ml of suspension. Patients on low sodium diets should be informed that this medicinal product is essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Voriconazole is metabolised by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolised by these CYP450 isoenzymes, in particular for substances metabolised by CYP3A4 since voriconazole is a strong CYP3A4 inhibitor though the increase in AUC is substrate dependent (see Table below).</p><p>&nbsp;</p><p>Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200&nbsp;mg twice daily (BID). These results are relevant to other populations and routes of administration.</p><p>&nbsp;</p><p>Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide and ivabradine), coadministration is contraindicated (see below and section 4.3).</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interactions between voriconazole and other medicinal products are listed in the table below (once daily as &ldquo;QD&rdquo;, twice daily as &ldquo;BID&rdquo;, three times daily as &ldquo;TID&rdquo; and not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range. The asterisk (*) indicates a two-way interaction. AUC<sub>t</sub>, AUC<sub>t</sub> and AUC<sub>0-</sub><sub>&yen;</sub> represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.</p><p>&nbsp;</p><p>The interactions in the table are presented in the following order: contraindications, those requiring dose adjustment and careful clinical and/or biological monitoring, and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top">&nbsp;<p><strong>Medicinal product<br /><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction<br />Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning<br />coadministration</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Astemizole, cisapride, pimozide, quinidine, terfenadine and ivabradine</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine and long-acting barbiturates (including but not limited to: phenobarbital, mephobarbital)<br /><em>[potent CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Although not studied, carbamazepine and long-acting barbiturates are likely to significantly decrease plasma voriconazole concentrations.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (a non-nucleoside reverse transcriptase inhibitor) <em>[CYP450 inducer; CYP3A4 inhibitor and substrate]</em></p><p><em>&nbsp;</em></p><p>Efavirenz 400&nbsp;mg QD, coadministered with voriconazole 200 mg BID<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz 300&nbsp;mg QD, coadministered with voriconazole 400&nbsp;mg BID<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz C<sub>max</sub> &shy; 38%<br />Efavirenz AUCt &shy; 44%</p><p>Voriconazole C<sub>max</sub> &macr; 61%<br />Voriconazole AUCt &macr; 77%</p><p>&nbsp;</p><p>&nbsp;</p><p>Compared to efavirenz 600 mg QD,</p><p>Efavirenz C<sub>max</sub> &harr;<br />Efavirenz AUCt &shy; 17%<br />&nbsp;</p><p>Compared to voriconazole 200&nbsp;mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 23%<br />Voriconazole AUCt &macr; 7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Use of standard doses of voriconazole with efavirenz doses of 400&nbsp;mg QD or higher is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400&nbsp;mg BID and the efavirenz dose is decreased to 300&nbsp;mg QD. When voriconazole treatment is stopped, the initial dose of efavirenz should be restored (see sections 4.2 and 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Ergot alkaloids (including but not limited to: ergotamine and dihydroergotamine)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ergot alkaloids and lead to ergotism.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Lurasidone</p><p><em>[CYP3A4 substrate]</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Although not studied,</p><p>voriconazole is likely to significantly increase the plasma concentrations of lurasidone.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Naloxegol</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of naloxegol.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p><em>[potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300&nbsp;mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 350&nbsp;mg BID)<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 400&nbsp;mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> &macr; 69%<br />Voriconazole AUCt &macr; 78%</p><p>&nbsp;</p><p>Compared to voriconazole 200&nbsp;mg BID,</p><p>Voriconazole C<sub>max</sub> &macr; 4%<br />Voriconazole AUCt &macr; 32%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rifabutin C<sub>max</sub> &shy; 195%<br />Rifabutin AUCt &shy; 331%</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 104%<br />Voriconazole AUCt &shy; 87%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.</p><p>The maintenance dose of voriconazole may be increased to 5&nbsp;mg/kg intravenously BID or from 200&nbsp;mg to 350&nbsp;mg orally BID (100&nbsp;mg to 200&nbsp;mg orally BID in patients less than 40&nbsp;kg) (see section 4.2).</p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin (600&nbsp;mg QD)<br /><em>[potent CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &macr; 93%<br />Voriconazole AUCt &macr; 96%</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir (protease inhibitor)<br /><em>[potent CYP450 inducer; CYP3A4 inhibitor and substrate]</em><br />&nbsp;</p><p>High dose (400&nbsp;mg BID)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;Low dose (100&nbsp;mg BID)<sup>*</sup><br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ritonavir C<sub>max</sub> and AUCt &harr;<br />Voriconazole C<sub>max</sub> &macr; 66%<br />Voriconazole AUCt &macr; 82%<br />&nbsp;</p><p>&nbsp;</p><p>Ritonavir C<sub>max</sub> &macr; 25%<br />Ritonavir AUCt &macr;13%<br />Voriconazole C<sub>max</sub> &macr; 24%<br />Voriconazole AUCt &macr; 39%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and high doses of ritonavir (400&nbsp;mg and above BID) is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of voriconazole and low-dose ritonavir (100&nbsp;mg BID) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s Wort</p><p><em>[CYP450 inducer; P-gp&nbsp;inducer]</em></p><p>300&nbsp;mg TID (coadministered with voriconazole 400&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Voriconazole AUC<sub>0-</sub><sub>&yen;</sub> &macr; 59%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Tolvaptan</p><p><em>[CYP3A substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of tolvaptan.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Venetoclax</p><p><em>[CYP3A substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of venetoclax.</p></td><td style="vertical-align:top"><p>Concomitant administration of voriconazole is <strong>contraindicated </strong>at initiation and during venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole (200&nbsp;mg QD)<br /><em>[CYP2C9, CYP2C19 and CYP3A4 inhibitor]</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &shy; 57%<br />Voriconazole AUCt &shy; 79%</p><p>Fluconazole C<sub>max</sub> ND<br />Fluconazole AUCt ND</p><p><br />&nbsp;</p></td><td style="vertical-align:top"><p>The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin<br /><em>[CYP2C9 substrate and potent CYP450 inducer]</em></p><p><em>&nbsp;</em></p><p>300&nbsp;mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 400&nbsp;mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> &macr; 49%<br />Voriconazole AUCt &macr; 69%</p><p>&nbsp;</p><p>&nbsp;</p><p>Phenytoin C<sub>max</sub> &shy; 67%<br />Phenytoin AUCt &shy; 81%</p><p>Compared to voriconazole 200&nbsp;mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 34%<br />Voriconazole AUCt &shy; 39%</p></td><td style="vertical-align:top"><p>Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk. Careful monitoring of phenytoin plasma levels is recommended.</p><p>&nbsp;</p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5&nbsp;mg/kg IV BID or from 200&nbsp;mg to 400&nbsp;mg oral BID (100&nbsp;mg to 200&nbsp;mg oral BID in patients less than 40&nbsp;kg) (see section 4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Letermovir</p><p><em>[CYP2C9 and CYP2C19 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &darr; 39%</p><p>Voriconazole AUC<sub>0-12</sub> &darr; 44%</p><p>Voriconazole C<sub>12</sub>&nbsp;&darr; 51%</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with letermovir cannot be avoided, monitor for loss of voriconazole effectiveness.</p></td></tr><tr><td style="vertical-align:top"><p>Flucloxacillin<br /><em>[CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Significantly decreased plasma voriconazole concentrations have been reported.</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with flucloxacillin cannot be avoided, monitor for potential loss of voriconazole effectiveness (e.g., by therapeutic drug monitoring); increasing the dose of voriconazole may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Glasdegib<br /><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of glasdegib and increase risk of QTc prolongation.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, frequent ECG monitoring is recommended (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Tyrosine kinase inhibitors (including but not limited to: axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase plasma concentrations of tyrosine kinase inhibitors metabolised by CYP3A4.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor and close clinical monitoring is recommended (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p><p>&nbsp;</p><p>Warfarin (30&nbsp;mg single dose, coadministered with 300&nbsp;mg BID voriconazole)</p><p><em>[CYP2C9 substrate]</em></p><p><em>&nbsp;</em></p><p>Other oral coumarins<br />(including but not limited to:&nbsp;phenprocoumon, acenocoumarol)</p><p><em>[CYP2C9 and CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Maximum increase in prothrombin time was approximately 2-fold.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole may increase the plasma concentrations of coumarins that may cause an increase in prothrombin time.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Close monitoring of prothrombin time or other suitable anticoagulation tests is recommended, and the dose of anticoagulants should be adjusted accordingly.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ivacaftor</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ivacaftor with risk of increased adverse reactions.</p></td><td style="vertical-align:top"><p>Dose reduction of ivacaftor is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines</p><p><em>[CYP3A4 substrates]</em></p><p>Midazolam (0.05 mg/kg IV single dose)</p><p>&nbsp;</p><p>Midazolam (7.5 mg oral single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>Other benzodiazepines (including but not limited to: triazolam, alprazolam)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Midazolam AUC<sub>0-</sub><sub>&yen;</sub> &shy; 3.7-fold</p><p>&nbsp;</p><p>In an independent published study,</p><p>Midazolam C<sub>max</sub> &shy; 3.8-fold</p><p>Midazolam AUC<sub>0-</sub><sub>&yen;</sub> &shy; 10.3-fold</p><p>&nbsp;</p><p>Although not studied , voriconazole is likely to increase the plasma concentrations of other benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect.</p></td><td style="vertical-align:top"><p>Dose reduction of benzodiazepines should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p><em>[CYP3A4 substrates]</em></p><p><em>&nbsp;</em></p><p>Sirolimus (2&nbsp;mg single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Everolimus</p><p><em>[also P‑gp substrate]</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin (in stable renal transplant recipients receiving chronic ciclosporin therapy)<br />&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus (0.1&nbsp;mg/kg single dose)<br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study, Sirolimus C<sub>max</sub> &shy; 6.6-fold<br />Sirolimus AUC<sub>0-</sub><sub>&yen;</sub> &shy; 11-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of everolimus.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin C<sub>max</sub> &shy; 13%<br />Ciclosporin AUCt &shy; 70%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus C<sub>max</sub> &shy; 117%<br />Tacrolimus AUC<sub>t</sub> &shy; 221%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and sirolimus is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of voriconazole and everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations (see section 4.4).</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored. Increased ciclosporin levels have been associated with nephrotoxicity. <u>When voriconazole is discontinued, ciclosporin levels must be carefully monitored and the dose increased as necessary</u>.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored. Increased tacrolimus levels have been associated with nephrotoxicity. <u>When voriconazole is discontinued, tacrolimus levels must be carefully monitored and the dose increased as necessary</u>.</p></td></tr><tr><td style="vertical-align:top"><p>Long-Acting Opiates</p><p><em>[CYP3A4 substrates]</em><br />&nbsp;</p><p>Oxycodone (10&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Oxycodone C<sub>max</sub> &shy; 1.7-fold<br />Oxycodone AUC<sub>0-</sub><sub>&yen;</sub> &shy; 3.6-fold<br />&nbsp;</p></td><td style="vertical-align:top"><p>Dose reduction in oxycodone and other long-acting opiates metabolised by CYP3A4 (e.g.,&nbsp;hydrocodone) should be considered. Frequent monitoring for opiate‑associated adverse reactions may be necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Methadone (32-100&nbsp;mg QD)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>R-methadone (active) C<sub>max</sub> &shy; 31%<br />R-methadone (active) AUCt &shy; 47%<br />S-methadone C<sub>max</sub> &shy; 65%<br />S-methadone AUCt &shy; 103%</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended. Dose reduction of methadone may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) <em>[CYP2C9 substrates]</em></p><p><em>&nbsp;</em></p><p>Ibuprofen (400&nbsp;mg single dose)</p><p>&nbsp;</p><p>Diclofenac (50&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>S-Ibuprofen C<sub>max</sub> &shy; 20%<br />S-Ibuprofen AUC<sub>0-</sub><sub>&yen;</sub> &shy; 100%</p><p>&nbsp;</p><p>Diclofenac C<sub>max</sub> &shy; 114%<br />Diclofenac AUC<sub>0-</sub><sub>&yen;</sub> &shy; 78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended. Dose reduction of NSAIDs may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole (40&nbsp;mg QD)<sup>*</sup><br /><em>[CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate]</em></p><p><em>&nbsp;</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Omeprazole C<sub>max</sub> &shy; 116%<br />Omeprazole AUCt &shy; 280%</p><p>Voriconazole C<sub>max</sub> &shy; 15%<br />Voriconazole AUCt &shy; 41%</p><p>&nbsp;</p><p>Other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these medicinal products.</p></td><td style="vertical-align:top"><p>No dose adjustment of voriconazole is recommended.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already receiving omeprazole doses of 40&nbsp;mg or above, it is recommended that the omeprazole dose be halved.</p></td></tr><tr><td style="vertical-align:top"><p>Oral Contraceptives<sup>*</sup></p><p><em>[CYP3A4 substrate; CYP2C19 inhibitor]</em></p><p>Norethisterone/ethinylestradiol (1&nbsp;mg/0.035&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>Ethinylestradiol C<sub>max</sub> &shy; 36%<br />Ethinylestradiol AUCt &shy; 61%</p><p>Norethisterone C<sub>max</sub> &shy; 15%<br />Norethisterone AUCt &shy; 53%</p><p>Voriconazole C<sub>max</sub> &shy; 14%<br />Voriconazole AUCt &shy; 46%</p></td><td style="vertical-align:top"><p>Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Short-acting Opiates</p><p><em>[CYP3A4 substrates]</em><br />&nbsp;</p><p>Alfentanil (20&nbsp;&mu;g/kg single dose, with concomitant naloxone)<br />&nbsp;</p><p>Fentanyl (5&nbsp;g/kg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Alfentanil AUC<sub>0-</sub><sub>&yen;</sub> &shy; 6-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Fentanyl AUC<sub>0-</sub><sub>&yen;</sub> &shy; 1.34-fold</p></td><td style="vertical-align:top"><p>Dose reduction of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g.,&nbsp;sufentanil) should be considered. Extended and frequent monitoring for respiratory depression and other opiate‑associated adverse reactions is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Statins (e.g., lovastatin)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of statins that are metabolised by CYP3A4 and could lead to rhabdomyolysis.</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with statins metabolised by CYP3A4 cannot be avoided, dose reduction of the statin should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sulfonylureas (including but not limited to: tolbutamide, glipizide, glyburide)</p><p><em>[CYP2C9 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of sulfonylureas and cause hypoglycaemia.</p></td><td style="vertical-align:top"><p>Careful monitoring of blood glucose is recommended. Dose reduction of sulfonylureas should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Vinca Alkaloids (including but not limited to: vincristine and vinblastine)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of vinca alkaloids and lead to neurotoxicity.</p></td><td style="vertical-align:top"><p>Dose reduction of vinca alkaloids should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Other HIV Protease Inhibitors (including but not limited to: saquinavir, amprenavir and nelfinavir)<sup>*</sup><br /><em>[CYP3A4 substrates and inhibitors]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro</em> studies show that voriconazole may inhibit the metabolism of HIV protease inhibitors and the metabolism of voriconazole may also be inhibited by HIV protease inhibitors.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (including but not limited to: delavirdine, nevirapine)<sup>*</sup><br /><em>[CYP3A4 substrates, inhibitors or CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Not studied clinically.<em> In vitro</em> studies show that the metabolism of voriconazole may be inhibited by NNRTIs and voriconazole may inhibit the metabolism of NNRTIs.</p><p>The findings of the effect of efavirenz on voriconazole suggest that the metabolism of voriconazole may be induced by an NNRTI.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Tretinoin</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase tretinoin concentrations and increase risk of adverse reactions (pseudotumor cerebri, hypercalcaemia).</p></td><td style="vertical-align:top"><p>Dose adjustment of tretinoin is recommended during treatment with voriconazole and after its discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine (400&nbsp;mg BID)<br /><em>[non-specific CYP450 inhibitor and increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &shy; 18%<br />Voriconazole AUCt &shy; 23%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin (0.25&nbsp;mg QD)<br /><em>[P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Digoxin C<sub>max</sub> &harr;<br />Digoxin AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir (800&nbsp;mg TID)<br /><em>[CYP3A4 inhibitor and substrate]</em></p></td><td style="vertical-align:top"><p>Indinavir C<sub>max</sub> &harr;<br />Indinavir AUCt &harr;</p><p>Voriconazole C<sub>max</sub> &harr;<br />Voriconazole AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;</p><p>Erythromycin (1&nbsp;g BID)<br /><em>[CYP3A4 inhibitor]</em></p><p>&nbsp;</p><p>Azithromycin (500&nbsp;mg QD)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p><p>&nbsp;</p><p>The effect of voriconazole on either erythromycin or azithromycin is unknown.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mycophenolic acid (1&nbsp;g single dose)</p><p><em>[UDP-glucuronyl transferase substrate]</em></p></td><td style="vertical-align:top"><p>Mycophenolic acid C<sub>max</sub> &harr;<br />Mycophenolic acid AUC<sub>t</sub> &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids</p><p>&nbsp;</p><p>Prednisolone (60&nbsp;mg single dose)<br /><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Prednisolone C<sub>max</sub> &shy; 11%<br />Prednisolone AUC<sub>0-</sub><sub>&yen;</sub> &shy; 34%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>No dose adjustment</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine (150&nbsp;mg BID)<br /><em>[increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p>There are no adequate data on the use of VFEND in pregnant women available.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>VFEND must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Women of child-bearing potential </u></p><p>Women of child-bearing potential must always use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with VFEND.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In an animal study, no impairment of fertility was demonstrated in male and female rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VFEND has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><u>Summary of safety profile</u></p><p>The safety profile of voriconazole in adults is based on an integrated safety database of more than 2,000&nbsp;subjects (including 1,603 adult patients in therapeutic trials) and an additional 270&nbsp;adults in prophylaxis trials. This represents a heterogeneous population, containing patients with haematological malignancy, HIV-infected patients with oesophageal candidiasis and refractory fungal infections, non‑neutropenic patients with candidaemia or aspergillosis and healthy volunteers.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were visual impairment, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, liver function test abnormal, respiratory distress and abdominal pain.</p><p>&nbsp;</p><p>The severity of the adverse reactions was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>In the table below, since the majority of the studies were of an open nature, all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic (1,603) and prophylaxis (270) studies, by system organ class, are listed.</p><p>&nbsp;</p><p>Frequency categories are expressed as: Very common (&sup3;1/10); Common (&sup3;1/100 to &lt;1/10); Uncommon (&sup3;1/1,000 to &lt;1/100); Rare (&sup3;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Undesirable effects reported in subjects receiving voriconazole:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>&ge; 1/10</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100</strong></p><p><strong>to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to &lt;</strong></p><p><strong>1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000 to &lt;</strong></p><p><strong>1/1,000</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>not known</strong></p><p><strong>(cannot be</strong></p><p><strong>estimated</strong></p><p><strong>from</strong></p><p><strong>available</strong></p><p><strong>data)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>pseudomembranous colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>squamous cell carcinoma (including cutaneous SCC in situ, or Bowen&rsquo;s disease)*,**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>1</sup>, pancytopenia, thrombocytopenia<sup>2</sup>, leukopenia, anaemia</p></td><td style="vertical-align:top"><p>bone marrow failure, lymphadenopathy, eosinophilia</p></td><td style="vertical-align:top"><p>disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>adrenal insufficiency, hypothyroidism</p></td><td style="vertical-align:top"><p>hyperthyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>oedema peripheral</p></td><td style="vertical-align:top"><p>hypoglycaemia, hypokalaemia, hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>depression, hallucination, anxiety, insomnia, agitation, confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>convulsion, syncope, tremor, hypertonia<sup>3</sup>, paraesthesia, somnolence, dizziness</p></td><td style="vertical-align:top"><p>brain oedema, encephalopathy<sup>4</sup>, extrapyramidal disorder<sup>5</sup>, neuropathy peripheral, ataxia, hypoaesthesia, dysgeusia</p></td><td style="vertical-align:top"><p>hepatic encephalopathy, Guillain-Barre syndrome, nystagmus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>visual impairment<sup>6</sup></p></td><td style="vertical-align:top"><p>retinal haemorrhage</p></td><td style="vertical-align:top"><p>optic nerve disorder<sup>7</sup>, papilloedema<sup>8</sup>, oculogyric crisis, diplopia, scleritis, blepharitis</p></td><td style="vertical-align:top"><p>optic atrophy, corneal opacity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypoacusis, vertigo, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arrhythmia supraventricular, tachycardia, bradycardia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular tachycardia</p></td><td style="vertical-align:top"><p>torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension, phlebitis</p></td><td style="vertical-align:top"><p>thrombophlebitis, lymphangitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>respiratory distress<sup>9</sup></p></td><td style="vertical-align:top"><p>acute respiratory distress syndrome, pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>cheilitis, dyspepsia, constipation, gingivitis</p></td><td style="vertical-align:top"><p>peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis, glossitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>liver function test abnormal</p></td><td style="vertical-align:top"><p>jaundice, jaundice cholestatic, hepatitis<sup>10</sup></p></td><td style="vertical-align:top"><p>hepatic failure, hepatomegaly, cholecystitis, cholelithiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>dermatitis exfoliative, alopecia, rash maculo-papular, pruritus, erythema, phototoxicity**</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>8</sup>, purpura, urticaria, dermatitis allergic, rash papular, rash macular, eczema</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis<sup>8</sup>, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>8, </sup>angioedema, actinic keratosis*, pseudoporphyria, erythema multiforme, psoriasis, drug eruption</p></td><td style="vertical-align:top"><p>cutaneous lupus erythematosus*, ephelides*, lentigo*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>arthritis, periostitis*,**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure acute, haematuria</p></td><td style="vertical-align:top"><p>renal tubular necrosis, proteinuria, nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia</p></td><td style="vertical-align:top"><p>chest pain, face oedema<sup>11</sup>, asthenia, chills</p></td><td style="vertical-align:top"><p>infusion site reaction, influenza like illness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood creatinine increased</p></td><td style="vertical-align:top"><p>blood urea increased, blood cholesterol increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*ADR identified post-marketing</p><p>**Frequency category is based on an observational study utilising real-world data from secondary data sources in Sweden</p><p><sup>1 </sup>Includes febrile neutropenia and neutropenia.</p><p><sup>2</sup> Includes immune thrombocytopenic purpura.</p><p><sup>3</sup> Includes nuchal rigidity and tetany.</p><p><sup>4</sup> Includes hypoxic-ischaemic encephalopathy and metabolic encephalopathy.</p><p><sup>5</sup> Includes akathisia and parkinsonism.</p><p><sup>6</sup> See &ldquo;Visual impairments&rdquo; paragraph in section 4.8.</p><p><sup>7</sup> Prolonged optic neuritis has been reported post-marketing. See section 4.4.</p><p><sup>8</sup> See section 4.4.</p><p><sup>9</sup> Includes dyspnoea and dyspnoea exertional.</p><p><sup>10</sup> Includes drug-induced liver injury, hepatitis toxic, hepatocellular injury and hepatotoxicity.</p><p><sup>11</sup> Includes periorbital oedema, lip oedema, and oedema mouth.</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions </u></p><p><em>&nbsp;</em></p><p><em>Altered taste perception </em></p><p>In the combined data from three bioequivalence studies using the powder for oral suspension formulation, treatment-related taste perversion was recorded in 12 (14%) of subjects.</p><p>&nbsp;</p><p><em>Visual impairments </em></p><p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, colour blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, and xanthopsia) with voriconazole were very common. These visual impairments were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed. There was evidence of attenuation with repeated doses of voriconazole. The visual impairments were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual impairments may be associated with higher plasma concentrations and/or doses.</p><p>&nbsp;</p><p>The mechanism of action is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.</p><p>&nbsp;</p><p>There have been post-marketing reports of prolonged visual adverse events (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Dermatological reactions </em></p><p>Dermatological reactions were very common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medicinal products. The majority of rashes were of mild to moderate severity. Patients have developed severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) (uncommon), toxic epidermal necrolysis (TEN) (rare), drug reaction with eosinophilia and systemic symptoms (DRESS) (rare) and erythema multiforme (rare) during treatment with VFEND (see section 4.4).</p><p>&nbsp;</p><p>If a patient develops a rash they should be monitored closely and VFEND discontinued if lesions progress. Photosensitivity reactions such as ephelides, lentigo and actinic keratosis have been reported, especially during long-term therapy (see section 4.4).</p><p>&nbsp;</p><p>There have been reports of squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen&rsquo;s disease) in patients treated with VFEND for long periods of time; the mechanism has not been established (see section 4.4).</p><p>&nbsp;</p><p><em>Liver function tests </em></p><p>The overall incidence of transaminase increases &gt;3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use. Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p><p>&nbsp;</p><p>Voriconazole has been associated with cases of serious hepatic toxicity in patients with other serious underlying conditions. This includes cases of jaundice, hepatitis and hepatic failure leading to death (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Prophylaxis<strong> </strong></em></p><p>In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm. Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>The safety of voriconazole was investigated in 288 paediatric patients aged 2 to &lt;12 years (169) and 12 to &lt;18&nbsp;years (119) who received voriconazole for prophylaxis (183) and therapeutic use (105) in clinical trials. The safety of voriconazole was also investigated in 158 additional paediatric patients aged 2 to &lt;12&nbsp;years in compassionate use programs. Overall, the safety profile of voriconazole in paediatric population was similar to that in adults. However, a trend towards a higher frequency of liver enzyme elevations, reported as adverse events in clinical trials was observed in paediatric patients as compared to adults (14.2% transaminases increased in paediatrics compared to 5.3% in adults). Post-marketing data suggest there might be a higher occurrence of skin reactions (especially erythema) in the paediatric population compared to adults. In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1). There have been post-marketing reports of pancreatitis in paediatric patients.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; SFDA call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials there were 3 cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse reaction of photophobia of 10 minutes duration was reported.</p><p>&nbsp;</p><p>There is no known antidote to voriconazole.</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121&nbsp;ml/min. In an overdose, haemodialysis may assist in the removal of voriconazole from the body.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02A C03</p><p><u>&nbsp;</u></p><p><u>Mode of action</u></p><p>Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742&nbsp;ng/ml (inter‑quartile range 2027 to 6302 ng/ml), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found and this relationship has not been explored in prophylaxis studies.</p><p>&nbsp;</p><p>Pharmacokinetic-Pharmacodynamic analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both liver function test abnormalities and visual disturbances. Dose adjustments in prophylaxis studies have not been explored.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety </u></p><p><em>In vitro</em>, voriconazole displays broad-spectrum antifungal activity with antifungal potency against <em>Candida </em>species (including fluconazole-resistant <em>C. krusei </em>and resistant strains of <em>C. glabrata</em> and <em>C. albicans</em>) and fungicidal activity against all <em>Aspergillus </em>species tested. In addition voriconazole shows <em>in vitro</em> fungicidal activity against emerging fungal pathogens, including those such as <em>Scedosporium</em> or <em>Fusarium</em> which have limited susceptibility to existing antifungal agents.</p><p>&nbsp;</p><p>Clinical efficacy defined as partial or complete response, has been demonstrated for <em>Aspergillus</em> spp. including <em>A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans; Candida </em>spp.<em>, </em>including<em> C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis; </em>and limited numbers of<em> C. dubliniensis, C. inconspicua, </em>and<em> C. guilliermondii, Scedosporium</em> spp., including<em> S. apiospermum, S. prolificans; </em>and <em>Fusarium</em> spp.</p><p>&nbsp;</p><p>Other treated fungal infections (often with either partial or complete response) included isolated cases of <em>Alternaria </em>spp., <em>Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium </em>spp<em>.,Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium spp. including P. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis and Trichosporon </em>spp. including<em> T. beigelii </em>infections.</p><p>&nbsp;</p><p><em>In vitro</em> activity against clinical isolates has been observed for <em>Acremonium </em>spp., <em>Alternaria </em>spp., <em>Bipolaris </em>spp<em>., Cladophialophora</em> spp.<em>, </em>and<em> Histoplasma capsulatum, </em>with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 &micro;g/ml.</p><p>&nbsp;</p><p><em>In vitro </em>activity against the following pathogens has been shown, but the clinical significance is unknown: <em>Curvularia</em> spp. and<em> Sporothrix</em> spp.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>&nbsp;</p><p>The species most frequently involved in causing human infections include <em>C. albicans, C. parapsilosis, C. tropicalis, C. glabrata </em>and<em> C. krusei</em>, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1&nbsp;mg/L for voriconazole.</p><p>&nbsp;</p><p>However, the<em> in vitro</em> activity of voriconazole against <em>Candida </em>species is not uniform. Specifically, for<br /><em>C. glabrata, </em>the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are those of fluconazole-susceptible isolates. Therefore, every attempt should be made to identify <em>Candida</em> to species level. If antifungal susceptibility testing is available, the MIC results may be interpreted using breakpoint criteria established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p><u>&nbsp;</u></p><p><u>EUCAST Breakpoints</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Candida and Aspergillus species</p></td><td colspan="2" style="vertical-align:top"><p>Minimal Inhibitory Concentration (MIC) breakpoint (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p>&le;S (Susceptible)</p></td><td style="vertical-align:top"><p>&gt;R (Resistant)</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida dubliniensis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata</em></p></td><td style="vertical-align:top"><p>Insufficient evidence (IE)</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei</em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida guilliermondii<sup>2</sup></em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints for<em> Candida<sup>3</sup></em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus fumigatus<sup>4</sup></em></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus nidulans<sup>4</sup></em></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus flavus<strong> </strong></em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus niger</em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus terreus</em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>6</sup></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup> Strains with MIC values above the Susceptible/Intermediate (S/I) breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A&nbsp;clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of <em>C. albicans, C. dubliniensis, C. parapsilosis </em>and <em>C. tropicalis</em> are considered susceptible.</p><p><sup>2</sup> The epidemiological cut-off values (ECOFFs) for these species are in general higher than for <em>C. albicans</em>.</p><p><sup>3</sup> Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific <em>Candida</em> species. They are for use only for organisms that do not have specific breakpoints.</p><p><sup>4</sup> Area of technical uncertainty (ATU) is 2. Report as R with the following comment: &quot;In some clinical situations (non-invasive infections forms) voriconazole can be used provided sufficient exposure is ensured&quot;.</p><p><sup>5</sup> The ECOFFs for these species are in general one two-fold dilution higher than for <em>A. fumigatus</em>.</p><p><sup>6 </sup>Non-species related breakpoints have not been determined.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical experience </u></p><p>Successful outcome in this section is defined as complete or partial response.</p><p>&nbsp;</p><p><em><u>Aspergillus</u></em><u> infections &ndash; efficacy in aspergillosis patients with poor prognosis </u></p><p>Voriconazole has <em>in vitro </em>fungicidal activity against <em>Aspergillus </em>spp. The efficacy and survival benefit of voriconazole versus conventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in an open, randomised, multicentre study in 277 immunocompromised patients treated for 12&nbsp;weeks. Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12&nbsp;hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of 7&nbsp;days. Therapy could then be switched to the oral formulation at a dose of 200 mg every 12 hours. Median duration of IV voriconazole therapy was 10 days (range 2-85 days). After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2-232 days).</p><p>&nbsp;</p><p>A satisfactory global response (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of voriconazole-treated patients compared to 31% of patients treated with comparator. The 84-day survival rate for voriconazole was statistically significantly higher than that for the comparator and a clinically and statistically significant benefit was shown in favour of voriconazole for both time to death and time to discontinuation due to toxicity.</p><p>&nbsp;</p><p>This study confirmed findings from an earlier, prospectively designed study where there was a positive outcome in subjects with risk factors for a poor prognosis, including graft versus host disease, and, in particular, cerebral infections (normally associated with almost 100% mortality).</p><p>&nbsp;</p><p>The studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.</p><p>&nbsp;</p><p><u>Candidaemia in non-neutropenic patients </u></p><p>The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study. Three hundred and seventy non-neutropenic patients (above 12 years of age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole. Nine subjects in the voriconazole group and 5 in the amphotericin B followed by fluconazole group also had mycologically proven infection in deep tissue. Patients with renal failure were excluded from this study. The median treatment duration was 15&nbsp;days in both treatment arms. In the primary analysis, successful response as assessed by a Data Review Committee (DRC) blinded to study medicinal product was defined as resolution/improvement in all clinical signs and symptoms of infection with eradication of <em>Candida </em>from blood and infected deep tissue sites 12&nbsp;weeks after the end of therapy (EOT). Patients who did not have an assessment 12 weeks after EOT were counted as failures. In this analysis a successful response was seen in 41% of patients in both treatment arms.</p><p>&nbsp;</p><p>In a secondary analysis, which utilised DRC<em> </em>assessments at the latest evaluable time point (EOT, or 2, 6, or 12&nbsp;weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively.</p><p>&nbsp;</p><p>The Investigator&rsquo;s assessment of successful outcome at each of these time points is shown in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><em>Timepoint </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Voriconazole </em></strong></p><p><strong>(N=248)</strong></p></td><td style="vertical-align:top"><p><strong><em>Amphotericin B &rarr; fluconazole </em></strong></p><p><strong>(N=122)</strong></p></td></tr><tr><td><p>EOT</p></td><td><p>178 (72%)</p></td><td><p>88 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>2 weeks after EOT</p></td><td style="vertical-align:top"><p>125 (50%)</p></td><td style="vertical-align:top"><p>62 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>55 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>12 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>51 (42%)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Serious refractory <em>Candida</em> infections </u></p><p>The study comprised 55 patients with serious refractory systemic <em>Candida</em> infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective. Successful response was seen in 24 patients (15 complete, 9 partial responses). In fluconazole-resistant non-<em>albicans</em> species, a successful outcome was seen in 3/3 <em>C. krusei</em> (complete responses) and 6/8 <em>C. glabrata</em> (5 complete, 1 partial response) infections. The clinical efficacy data were supported by limited susceptibility data.</p><p>&nbsp;</p><p><em><u>Scedosporium</u></em><u> and <em>Fusarium</em> infections</u></p><p>Voriconazole was shown to be effective against the following rare fungal pathogens:</p><p>&nbsp;</p><p><em>Scedosporium</em> spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with <em>S. apiospermum </em>and in 2 (both partial responses) of 7 patients with <em>S. prolificans</em> infection. In addition, a successful response was seen in 1 of 3 patients with infections caused by more than one organism including <em>Scedosporium</em> spp.</p><p>&nbsp;</p><p><em>Fusarium</em> spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole. Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; 2 of them had a successful outcome.</p><p>&nbsp;</p><p>The majority of patients receiving voriconazole treatment of the above mentioned rare infections were intolerant of, or refractory to, prior antifungal therapy.</p><p>&nbsp;</p><p><u>Primary Prophylaxis of Invasive Fungal Infections &ndash; Efficacy in HSCT recipients without prior proven or probable IFI</u></p><p>Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI. Success was defined as the ability to continue study drug prophylaxis for 100 days after HSCT (without stopping for &gt;14 days) and survival with no proven or probable IFI for 180 days after HSCT. The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML. From all patients 58% were subject to myeloablative conditions regimens. Prophylaxis with study drug was started immediately after HSCT: 224 received voriconazole and 241 received itraconazole. The median duration of study drug prophylaxis was 96 days for voriconazole and 68 days for itraconazole in the MITT group.</p><p>&nbsp;</p><p>Success rates and other secondary endpoints are presented in the table below:</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole<br />N=224</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole<br />N=241</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI) </strong></p></td><td style="vertical-align:top"><p><strong>P-Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Success at day 180*</p></td><td style="vertical-align:top"><p>109 (48.7%)</p></td><td style="vertical-align:top"><p>80 (33.2%)</p></td><td style="vertical-align:top"><p>16.4% (7.7%, 25.1%)**</p></td><td style="vertical-align:top"><p>0.0002**</p></td></tr><tr><td style="vertical-align:top"><p>Success at day 100</p></td><td style="vertical-align:top"><p>121 (54.0%)</p></td><td style="vertical-align:top"><p>96 (39.8%)</p></td><td style="vertical-align:top"><p>15.4% (6.6%, 24.2%)**</p></td><td style="vertical-align:top"><p>0.0006**</p></td></tr><tr><td style="vertical-align:top"><p>Completed at least 100 days of study drug prophylaxis</p></td><td style="vertical-align:top"><p>120 (53.6%)</p></td><td style="vertical-align:top"><p>94 (39.0%)</p></td><td style="vertical-align:top"><p>14.6% (5.6%, 23.5%)</p></td><td style="vertical-align:top"><p>0.0015</p></td></tr><tr><td style="vertical-align:top"><p>Survived to day 180</p></td><td style="vertical-align:top"><p>184 (82.1%)</p></td><td style="vertical-align:top"><p>197 (81.7%)</p></td><td style="vertical-align:top"><p>0.4% (-6.6%, 7.4%)</p></td><td style="vertical-align:top"><p>0.9107</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI to day 180</p></td><td style="vertical-align:top"><p>3 (1.3%)</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td style="vertical-align:top"><p>-0.7% (-3.1%, 1.6%)</p></td><td style="vertical-align:top"><p>0.5390</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI to day 100</p></td><td style="vertical-align:top"><p>2 (0.9%)</p></td><td style="vertical-align:top"><p>4 (1.7%)</p></td><td style="vertical-align:top"><p>-0.8% (-2.8%, 1.3%)</p></td><td style="vertical-align:top"><p>0.4589</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI while on study drug</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3 (1.2%)</p></td><td style="vertical-align:top"><p>-1.2% (-2.6%, 0.2%)</p></td><td style="vertical-align:top"><p>0.0813</p></td></tr></tbody></table><p>* Primary endpoint of the study</p><p>** Difference in proportions, 95% CI and p-values obtained after adjustment for randomization</p><p>&nbsp;</p><p>The breakthrough IFI rate to Day 180 and the primary endpoint of the study, which is Success at Day&nbsp;180, for patients with AML and myeloablative conditioning regimens respectively, is presented in the table below:</p><p><strong>&nbsp;</strong></p><p><strong>AML</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole </strong></p><p><strong>(N=98) </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole</strong></p><p><strong>(N=109)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>1 (1.0%)</p></td><td style="vertical-align:top"><p>&nbsp;2 (1.8%)</p></td><td style="vertical-align:top"><p>-0.8% (-4.0%, 2.4%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>55 (56.1%)</p></td><td style="vertical-align:top"><p>45 (41.3%)</p></td><td style="vertical-align:top"><p>14.7% (1.7%, 27.7%)***</p></td></tr></tbody></table><p>*&nbsp;&nbsp; Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>***Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><strong>Myeloablative conditioning regimens</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole </strong></p><p><strong>(N=125) </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole</strong></p><p><strong>(N=143)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>2 (1.6%)</p></td><td style="vertical-align:top"><p>3 (2.1%)</p></td><td style="vertical-align:top"><p>-0.5% (-3.7%, 2.7%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>70 (56.0%)</p></td><td style="vertical-align:top"><p>53 (37.1%)</p></td><td style="vertical-align:top"><p>20.1% (8.5%, 31.7%)***</p></td></tr></tbody></table><p>*&nbsp;&nbsp; Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>*** Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Secondary Prophylaxis of IFI &ndash; Efficacy in HSCT recipients</u><u> </u><u>with prior proven or probable IFI</u></p><p>Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI. The primary endpoint was the rate of occurrence of proven and probable IFI during the first year after HSCT. The MITT group included 40&nbsp;patients with prior IFI, including 31 with aspergillosis, 5 with candidiasis, and 4 with other IFI. The median duration of study drug prophylaxis was 95.5 days in the MITT group.</p><p>&nbsp;</p><p>Proven or probable IFIs developed in 7.5% (3/40) of patients during the first year after HSCT, including one candidemia, one scedosporiosis (both relapses of prior IFI), and one zygomycosis. The survival rate at Day&nbsp;180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).</p><p>&nbsp;</p><p><u>Duration of treatment </u></p><p>In clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164&nbsp;patients receiving voriconazole for over 6 months.</p><p><u>&nbsp;</u></p><p><u>Paediatric population </u></p><p>Fifty-three paediatric patients aged 2 to &lt;18 years were treated with voriconazole in two prospective, open‑label, non-comparative, multi-center clinical trials. One study enrolled 31 patients with possible, proven or probable invasive aspergillosis (IA), of whom 14 patients had proven or probable IA and were included in the MITT efficacy analyses. The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 were included in the MITT efficacy analyses.&nbsp;For patients with IA the overall rates of global response at 6&nbsp;weeks were 64.3% (9/14), the global response rate was 40% (2/5) for patients 2 to &lt;12 years and 77.8% (7/9) for patients 12 to &lt;18 years of age. For patients with ICC the global response rate at EOT was 85.7% (6/7) and for patients with EC the global response rate at EOT was 70% (7/10). The overall rate of response (ICC and EC combined) was 88.9% (8/9) for 2 to &lt;12 years old and 62.5% (5/8) for 12 to &lt;18 years old.&nbsp;</p><p>&nbsp;</p><p><u>Clinical studies examining QTc interval </u></p><p>A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QTc interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placebo‑adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600&nbsp;mg of voriconazole were 5.1, 4.8, and 8.2&nbsp;msec, respectively and 7.0 msec for ketoconazole 800&nbsp;mg. No subject in any group had an increase in QTc of &ge; 60&nbsp;msec from baseline. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500&nbsp;msec.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics </u></p><p>The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200&nbsp;mg or 300&nbsp;mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.</p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200&nbsp;mg twice daily to 300&nbsp;mg twice daily leads to a 2.5-fold increase in exposure (AUC&tau;). The oral maintenance dose of 200&nbsp;mg (or 100 mg for patients less than 40 kg) achieves a voriconazole exposure similar to 3&nbsp;mg/kg IV. A 300&nbsp;mg (or 150 mg for patients less than 40 kg) oral maintenance dose achieves an exposure similar to 4&nbsp;mg/kg IV. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by Day 6 in the majority of subjects.</p><p>&nbsp;</p><p><u>Absorption </u></p><p>Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (C<sub>max</sub>) achieved 1-2 hours after dosing. The absolute bioavailability of voriconazole after oral administration is estimated to be 96%. Bioequivalence was established between the 200&nbsp;mg tablet and the 40&nbsp;mg/ml oral suspension when administered as a 200&nbsp;mg dose. When multiple doses of voriconazole oral suspension are administered with high fat meals, C<sub>max</sub> and AUC&tau; are reduced by 58% and 37% respectively. The absorption of voriconazole is not affected by changes in gastric pH.</p><p>&nbsp;</p><p><u>Distribution </u></p><p>The volume of distribution at steady state for voriconazole is estimated to be 4.6&nbsp;L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58%. Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro</em> studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes CYP2C19, CYP2C9 and CYP3A4.</p><p>&nbsp;</p><p>The inter-individual variability of voriconazole pharmacokinetics is high.</p><p><em>&nbsp;</em></p><p><em>In vivo</em> studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUC&tau;) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p><p>&nbsp;</p><p>The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.</p><p>&nbsp;</p><p><u>Elimination </u></p><p>Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.</p><p>&nbsp;</p><p>After administration of a radiolabelled dose of voriconazole, approximately 80% of the radioactivity is recovered in the urine after multiple intravenous dosing and 83% in the urine after multiple oral dosing. The majority (&gt;94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p><p>&nbsp;</p><p>The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 200&nbsp;mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups </u></p><p><em>&nbsp;</em></p><p><em>Gender </em></p><p>In an oral multiple-dose study, C<sub>max</sub> and AUC&tau; for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years)<em>. </em>In the same study, no significant differences in C<sub>max</sub> and AUC&tau; were observed between healthy elderly males and healthy elderly females (&ge;65 years).</p><p>&nbsp;</p><p>In the clinical programme, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In an oral multiple-dose study C<sub>max</sub> and AUC&tau; in healthy elderly males (&ge;65 years) were 61% and 86% higher, respectively, than in healthy young males (18-45 years). No significant differences in C<sub>max</sub> and AUC&tau; were observed between healthy elderly females (&ge;65 years) and healthy young females (18-45 years).</p><p>&nbsp;</p><p>In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescent patients aged 12 to &lt;17 years. Multiple intravenous doses of 3, 4, 6, 7 and 8&nbsp;mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4&nbsp;mg/kg, 6&nbsp;mg/kg, and 200&nbsp;mg twice daily were evaluated in 3 paediatric pharmacokinetic studies. Intravenous loading doses of 6&nbsp;mg/kg IV twice daily on day 1 followed by 4&nbsp;mg/kg intravenous dose twice daily and 300&nbsp;mg oral tablets twice daily were evaluated in one adolescent pharmacokinetic study. Larger inter-subject variability was observed in paediatric patients compared to adults.</p><p>&nbsp;</p><p>A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUC<sub>t</sub>) in children following administration of a 9&nbsp;mg/kg IV loading dose was comparable to that in adults following a 6&nbsp;mg/kg IV loading dose. The predicted total exposures in children following IV maintenance doses of 4 and 8&nbsp;mg/kg twice daily were comparable to those in adults following 3 and 4&nbsp;mg/kg IV twice daily, respectively. The predicted total exposure in children following an oral maintenance dose of 9&nbsp;mg/kg (maximum of 350&nbsp;mg) twice daily was comparable to that in adults following 200&nbsp;mg oral twice daily. An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9&nbsp;mg/kg oral dose.</p><p>&nbsp;</p><p>The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. Oral bioavailability may, however, be limited in paediatric patients with malabsorption and very low body weight for their age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>Voriconazole exposures in the majority of adolescent patients were comparable to those in adults receiving the same dosing regimens. However, lower voriconazole exposure was observed in some young adolescents with low body weight compared to adults. It is likely that these subjects may metabolise voriconazole more similarly to children than to adults. Based on the population pharmacokinetic analysis, 12- to 14-year-old adolescents weighing less than 50&nbsp;kg should receive children&rsquo;s doses (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>In an oral single-dose (200&nbsp;mg) study in subjects with normal renal function and mild (creatinine clearance 41-60 ml/min) to severe (creatinine clearance &lt;20&nbsp;ml/min) renal impairment, the pharmacokinetics of voriconazole were not significantly affected by renal impairment. The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>After an oral single-dose (200&nbsp;mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.</p><p>&nbsp;</p><p>In an oral multiple-dose study, AUC&tau; was similar in subjects with moderate hepatic cirrhosis (Child-Pugh&nbsp;B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200&nbsp;mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh&nbsp;C) (see sections 4.2 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose toxicity studies with voriconazole indicated the liver to be the target organ. Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents. In rats, mice and dogs, voriconazole also induced minimal adrenal changes. Conventional studies of safety pharmacology, genotoxicity or carcinogenic potential did not reveal a special hazard for humans.</p><p>&nbsp;</p><p>In reproduction studies, voriconazole was shown to be teratogenic in rats and embryotoxic in rabbits at systemic exposures equal to those obtained in humans with therapeutic doses. In the pre- and post-natal development study in rats at exposures lower than those obtained in humans with therapeutic doses, voriconazole prolonged the duration of gestation and labour and produced dystocia with consequent maternal mortality and reduced perinatal survival of pups. The effects on parturition are probably mediated by species-specific mechanisms, involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents. Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Silica Colloidal Anhydrous</p><p>Titanium Dioxide<br />Xanthan Gum<br />Sodium Citrate<br />Citric Acid Anhydrous<br />Sodium Benzoate<br />Natural Orange Flavour</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
2 years
The shelf life of the constituted suspension is 14 days. 
Constituted suspension: Store below 30°C; do not refrigerate or freeze.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>For storage conditions after constitution, see section 6.3.</p><p>Keep the container tightly closed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One 100 ml high-density polyethylene (HDPE) bottle (with a polypropylene child resistant closure) contains 45 g of powder for oral suspension. A measuring cup (graduated to indicate 23 ml), 5 ml oral syringe and a press-in bottle adaptor are also provided.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong><u>Constitution instructions: </u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tap the bottle to release the powder.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add 2 measuring cups of water, providing a total volume of 46 ml.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the closed bottle vigorously for about 1 minute.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove child-resistant cap. Press bottle adaptor into the neck of the bottle.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the cap.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Write the date of expiration of the constituted suspension on the bottle label (the shelf-life of the constituted suspension is 14 days).</p><p>&nbsp;</p><p>Following constitution, the volume of the suspension is 75 ml, providing a usable volume of 70 ml.</p><p>&nbsp;</p><p><strong><u>Instructions for use: </u></strong></p><p>Shake the closed bottle of constituted suspension for approximately 10 seconds before each use.</p><p>&nbsp;</p><p>Once constituted, VFEND oral suspension should only be administered using the oral syringe supplied with each pack. Refer to the patient leaflet for more detailed instructions for use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER 
Pfizer Europe MA EEIG, Belgium

MANUFACTURER:
Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>